🏷

Classifications

Harrison's Chapter

Mechanistic Nosology

👪

Inheritance

2

Mitochondrial inheritance HP:0001427

Classical LHON is caused by pathogenic variants in the mitochondrial genome and is transmitted exclusively down the maternal line. An affected or carrier woman transmits the variant to all of her offspring; an affected man transmits it to none. Most carriers are homoplasmic, but heteroplasmy occurs in a minority and means that a maternal relative of a proband may not carry the variant at all — molecular testing of each at-risk relative is therefore required rather than assumed transmission. Penetrance is incomplete and both sex- and age-dependent.

Mitochondrial inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE

Show evidence (5 references)

PMID:20301353 SUPPORT Human Clinical

"transmitted strictly by maternal inheritance."

GeneReviews states that LHON mtDNA variants are transmitted strictly maternally.

PMID:20301353 SUPPORT Human Clinical

"variant cannot transmit the variant to any of his offspring."

Confirms that affected or carrier males do not transmit the mtDNA variant, the defining asymmetry of maternal inheritance.

PMID:20301353 SUPPORT Human Clinical

"complicated by the sex- and age-dependent penetrance of the primary mtDNA"

Establishes that penetrance is both sex- and age-dependent, not complete.

+ 2 more references

Autosomal recessive HP:0000007

A clinically indistinguishable autosomal recessive form (arLHON, OMIM 619382) is caused by biallelic variants in nuclear genes encoding complex I subunits or assembly/maintenance factors — DNAJC30 (the p.Tyr51Cys founder allele, prevalent in Central and Eastern Europe), NDUFS2, MCAT, and NDUFA12. arLHON should be considered whenever the LHON phenotype is convincing but mtDNA testing is unrevealing. Notably, arLHON retains the same male predominance and incomplete penetrance as mtDNA-driven LHON.

Autosomal recessive inheritance Penetrance: INCOMPLETE

Show evidence (3 references)

PMID:37071596 SUPPORT Human Clinical

"Recently, biallelic mutations in the NDUFS2, DNAJC30, MCAT and NDUFA12 nuclear"

Identifies the nuclear genes whose biallelic variants define autosomal recessive LHON.

PMID:37071596 SUPPORT Human Clinical

"The discovery of arLHON cases breaks with the dogma of exclusive"

States explicitly that arLHON overturns the assumption of exclusively maternal inheritance.

PMID:35148383 SUPPORT Human Clinical

"of unreported variant carriers confirms sex-dependent incomplete penetrance of"

Shows that arLHON shares the sex-dependent incomplete penetrance of the mtDNA form.

◆

Subtypes

4

m.11778G>A (MT-ND4)

MT-ND4 hgnc:7459

Widely reported as the most frequent primary LHON mtDNA variant worldwide and as the one with the poorest natural prognosis for spontaneous visual recovery; both statements are the consensus clinical view rather than claims curated here against a quantitative source. It is the genotype targeted by lenadogene nolparvovec gene therapy and the genotype enrolled in the RESCUE, REVERSE, REFLECT and RESTORE trials. Risk of visual failure is increased on mtDNA haplogroup J2 and decreased on haplogroup H.

Show evidence (1 reference)

PMID:37071596 SUPPORT Human Clinical

"mutations in ND1, ND4 and ND6, respectively."

Assigns m.11778G>A to MT-ND4 among the three primary LHON mtDNA variants.

m.3460G>A (MT-ND1)

MT-ND1 hgnc:7455

The second classical primary LHON variant, affecting the MT-ND1 complex I subunit. Unlike m.11778G>A and m.14484T>C it is not preferentially found on a specific haplogroup background, although risk is increased when it occurs on haplogroup K.

Show evidence (1 reference)

PMID:17668373 SUPPORT Human Clinical

"mutation is present in haplogroup K. By contrast, the risk of visual failure is"

Documents the haplogroup K risk background specific to the m.3460G>A subtype.

m.14484T>C (MT-ND6)

MT-ND6 hgnc:7462

Conventionally regarded as the primary LHON variant with the highest rate of spontaneous visual recovery, and reported to be enriched in some founder populations (notably French-Canadian pedigrees); both are the consensus clinical view rather than claims curated here against a quantitative source. Its risk of visual failure is increased on mtDNA haplogroup J1.

Show evidence (1 reference)

PMID:17668373 SUPPORT Human Clinical

"haplogroup J (J2 for 11778G-->A and J1 for 14484T-->C) and when the 3460G-->A"

Assigns the J1 subclade risk background specifically to m.14484T>C.

Autosomal Recessive LHON (DNAJC30 and other nuclear genes) MONDO:0030309

DNAJC30 hgnc:16410 Autosomal recessive inheritance

Nuclear-encoded, autosomal recessive phenocopy of classical LHON caused by biallelic DNAJC30, NDUFS2, MCAT, or NDUFA12 variants. The acute and chronic ocular course mirrors mtDNA LHON, but affected individuals have an earlier age of onset and a substantially higher rate of visual recovery, both spontaneous and idebenone-associated.

Show evidence (2 references)

PMID:37071596 SUPPORT Human Clinical

"with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"

Establishes that the arLHON clinical presentation copies that of mtDNA LHON.

PMID:35148383 SUPPORT Human Clinical

"patients demonstrate an earlier age of disease onset and a higher rate of"

Documents the earlier onset and higher recovery rate distinguishing arLHON from the maternally inherited form.

?

Discussions and Knowledge Gaps

3

What determines which carriers of a primary LHON mtDNA variant convert to visual loss, and can conversion risk be predicted prospectively for an individual?

KNOWLEDGE GAP OPEN gap_lhon_penetrance_determinants

Attached to

pathophysiology#Penetrance Modulation by Genetic Background and Environmental Triggers

Primary LHON susceptibility variants occur in roughly 1 in 1,000 people — far more common than manifest disease — and even the best-characterised modifiers (mtDNA haplogroup, sex, smoking) leave most of the variance in conversion unexplained. No validated biomarker predicts conversion, and contemporary registry estimates of lifetime risk (17.5% in males, 5.4% in females) are substantially lower than older textbook figures, which has direct consequences for genetic counselling and for powering prevention trials in asymptomatic carriers.

Proposed experiments

Prospective biomarker cohort of asymptomatic LHON mtDNA carriers

prospective longitudinal biomarker cohort study

exp_lhon_carrier_conversion_cohort

Follow a large multicentre cohort of asymptomatic primary-variant carriers with serial spectral-domain OCT (peripapillary RNFL, macular GCL), colour vision, contrast sensitivity, and electrophysiology (PERG/photopic negative response) to identify structural or functional changes that precede conversion, and estimate their positive predictive value for visual loss.

Decision criterion

Identification of a pre-conversion measure whose change predicts subsequent visual loss with clinically useful sensitivity and specificity.

Would support

Conversion is preceded by a detectable subclinical structural or functional decline that can be used to time intervention.

Would refute

Conversion is abrupt and unheralded by any measurable pre-clinical change, making carrier surveillance non-informative.

Nuclear modifier association study in discordant carrier sibships

within-family genetic modifier association study

exp_lhon_nuclear_modifier_gwas

Perform genome-wide (or exome-wide) association and rare-variant burden testing on affected versus unaffected carriers drawn from the same pedigrees, matched for mtDNA haplogroup and smoking exposure, to identify nuclear loci that modulate conversion independently of the known mtDNA and environmental modifiers.

Decision criterion

Replicated association of one or more nuclear loci with conversion after conditioning on haplogroup and smoking.

Would support

Nuclear genetic background is a material determinant of LHON penetrance.

Would refute

Residual penetrance variance is environmental or stochastic rather than nuclear-genetic.

Show evidence (2 references)

PMID:34670133 SUPPORT Human Clinical

"previously-17.5% for males and 5.4% for females."

Contemporary registry risk estimates are markedly lower than historical figures, underscoring the unresolved penetrance question.

PMID:34670133 SUPPORT Human Clinical

"women, older adults, and younger children are also at risk."

Shows that the classic young-adult-male stereotype under-describes who is at risk, an open counselling problem.

Does intravitreal allotopic MT-ND4 gene therapy produce a real treatment effect over natural history, given that sham-injected fellow eyes improved to the same degree as treated eyes?

KNOWLEDGE GAP OPEN gap_lhon_gene_therapy_effect_identifiability

Attached to

pathophysiology#Complex I Subunit Missense Mutation

In RESCUE and REVERSE the within-patient design was invalidated by bilateral improvement after unilateral injection, plausibly explained by contralateral vector transfer demonstrated in nonhuman primates. Without an independent untreated control arm, the durable improvement observed to five years cannot be cleanly separated from spontaneous recovery. This is the central unresolved question for LHON gene therapy.

Proposed experiments

Gene therapy trial with a between-patient untreated comparator

randomised controlled trial with between-patient comparator

exp_lhon_gt_independent_control_trial

Run a randomised trial in which the comparator is an independent untreated (or rigorously matched external natural-history) group of patients rather than the fellow eye, stratified by genotype and time from symptom onset, so that the treatment effect is identifiable in the presence of contralateral vector spread.

Decision criterion

A statistically significant difference in best-corrected visual acuity between treated patients and the independent untreated comparator.

Would support

Allotopic ND4 gene therapy confers visual benefit beyond spontaneous recovery.

Would refute

The observed improvement reflects natural history rather than the vector.

Show evidence (2 references)

PMID:33298565 SUPPORT Human Clinical

"Unexpectedly, sustained visual improvement was observed in both"

The bilateral improvement is precisely what makes the treatment effect unidentifiable in these trials.

PMID:33298565 SUPPORT Human Clinical

"between the two treatment groups, was not met (P = 0.894)."

The primary endpoint failure is a direct statement of the identifiability problem.

Is NQO1 genotype a clinically actionable predictor of idebenone response in LHON?

KNOWLEDGE GAP OPEN gap_lhon_nqo1_idebenone_pharmacogenetics

Attached to

pathophysiology#Complex I Electron Transfer Deficiency

Idebenone's mechanism requires NQO1-mediated reduction before it can shuttle electrons to complex III, so variants lowering NQO1 protein levels are a mechanistically coherent candidate explanation for non-response — and the unreduced, oxidized drug actively inhibits complex I, so the stakes are higher than simple inefficacy. Aleo et al. (2024) demonstrated both the molecular effect and a corresponding clinical signal, but the clinical arm was a retrospective analysis of an already-treated cohort rather than a prospective genotype-stratified trial, and the authors themselves put it no more strongly than "suggest consideration". Whether NQO1 genotype should actually gate or modify prescribing is unresolved.

Proposed experiments

NQO1-genotype-stratified prospective idebenone trial

prospective pharmacogenetic stratified interventional study

exp_lhon_nqo1_stratified_idebenone_trial

Prospectively stratify LHON patients starting idebenone by NQO1 genotype/protein level and compare pre-specified visual-acuity response endpoints between strata, with paired measurement of NQO1 protein and idebenone reduction capacity in patient-derived cells.

Decision criterion

A clinically meaningful difference in idebenone response between low-NQO1 and normal-NQO1 strata.

Would support

NQO1 genotype should guide idebenone prescribing or dosing in LHON.

Would refute

NQO1 status does not usefully predict idebenone response, and non-response is driven by other factors.

Show evidence (2 references)

PMID:38272025 SUPPORT Human Clinical

"can neither predict nor understand the non-responders."

States the open problem this discussion records: idebenone non-responders can currently be neither predicted nor explained.

PMID:38272025 PARTIAL Human Clinical

"suggest consideration of patient NQO1 genotype and mitochondrial DNA mutation in the context of idebenone therapy."

The proposed answer is offered as a consideration rather than a validated rule, which is precisely why this remains an open gap requiring a prospective stratified trial.

⚙

Pathophysiology

7

Complex I Subunit Missense Mutation

The initiating lesion is a missense point mutation in a gene encoding a core subunit of respiratory-chain complex I (NADH:ubiquinone oxidoreductase). The large majority of molecularly resolved classical cases carry one of three usually homoplasmic mtDNA variants — m.11778G>A in MT-ND4, m.3460G>A in MT-ND1, or m.14484T>C in MT-ND6, which together are responsible for the majority of LHON cases worldwide. In arLHON the equivalent lesion is biallelic disruption of a nuclear complex I subunit or assembly/maintenance factor (DNAJC30, NDUFS2, MCAT, NDUFA12). Because mtDNA is present in every cell, the mutation itself is systemic; the disease phenotype is not.

MT-ND4 hgnc:7459 MT-ND1 hgnc:7455 MT-ND6 hgnc:7462 DNAJC30 hgnc:16410

NADH dehydrogenase (ubiquinone) activity GO:0008137 ↓ DECREASED

mitochondrial inner membrane GO:0005743

Downstream

Complex I Electron Transfer Deficiency Missense substitution of a core complex I subunit degrades assembly and/or catalytic function of the NADH:ubiquinone oxidoreductase holoenzyme, impairing electron transfer from NADH to ubiquinone.

Show evidence (4 references)

PMID:37071596 SUPPORT Human Clinical

"in the mitochondrial genome, mainly the m.3460G>A, m.11778G>A and m.14484T>C"

Names the three primary mtDNA variants that constitute the initiating lesion.

PMID:34311469 SUPPORT Human Clinical

"oxidoreductase (complex I) have been found to be responsible for the majority of LHON cases worldwide."

Confirms that the three complex I subunit mutations account for the majority of LHON cases worldwide.

PMID:37071596 SUPPORT Human Clinical

"mutations in ND1, ND4 and ND6, respectively."

Maps each primary variant to its complex I subunit gene.

+ 1 more reference

Complex I Electron Transfer Deficiency

Mutant complex I transfers electrons from NADH to ubiquinone inefficiently. Proton pumping across the inner membrane falls, the NADH/NAD+ redox couple shifts, and the coupled ATP-generating capacity of oxidative phosphorylation is reduced. The severity of the biochemical lesion is not uniform across the three primary variants: transmitochondrial cybrid work shows a frank assembly and catalytic-activity defect for m.3460G>A, whereas m.11778G>A and m.14484T>C are generally reported to impair coupling efficiency and raise ROS with comparatively better preserved catalytic activity, so this node should be read as a shared functional endpoint rather than an identical molecular block. Idebenone's therapeutic rationale is to accept electrons via NQO1 and deliver them downstream to complex III, partly bypassing this block.

mitochondrial electron transport, NADH to ubiquinone GO:0006120 ↓ DECREASED oxidative phosphorylation GO:0006119 ↓ DECREASED

mitochondrial inner membrane GO:0005743

Downstream

ATP Deficit and Reactive Oxygen Species Overproduction Reduced electron flux through complex I lowers ATP output while increasing electron leak, raising superoxide and downstream reactive oxygen species production.

Show evidence (3 references)

PMID:38540197 SUPPORT Human Clinical

"mitochondrial gene mutations that hinder oxidative phosphorylation and increase"

Directly links the mitochondrial gene mutations to impaired oxidative phosphorylation.

PMID:34311469 SUPPORT In Vitro

"manifested as defects in the assembly and activity of complex I, respiratory"

Transmitochondrial cybrid experiments demonstrate the assembly and activity defect of complex I directly, the primary experimental evidence base for this node.

PMID:34311469 SUPPORT In Vitro

"deficiency, diminished mitochondrial adenosine triphosphate production, and"

Cybrid data link the complex I defect to reduced mitochondrial ATP production, the coupled-output claim of this node.

ATP Deficit and Reactive Oxygen Species Overproduction

The combination of a bioenergetic shortfall and increased electron leak creates chronic oxidative stress. Cybrid experiments show directly that the primary mutations raise mitochondrial ROS production while lowering ATP output and membrane potential, and that this is coupled to apoptotic activation (cytochrome c release, BAK/BAX, cleaved caspases) and impaired PINK1/parkin mitophagy. Why the resulting injury is confined to retinal ganglion cells remains unsettled. One proposed explanation is that RGCs regulate superoxide unusually tightly and that LHON mutations subvert that regulation — but the supporting measurement was made in the RGC-5 cell line, which was subsequently shown not to be of retinal ganglion cell origin, so this should be treated as an unconfirmed hypothesis. The better-supported account of selective vulnerability is the anatomical one given in the downstream node: the long, partly unmyelinated intraretinal axon segment imposes an exceptionally high and spatially distributed ATP demand.

Retinal ganglion cell CL:0000740

reactive oxygen species metabolic process GO:0072593 ↑ INCREASED ATP synthesis coupled electron transport GO:0042773 ↓ DECREASED response to oxidative stress GO:0006979 ↑ INCREASED

Downstream

Retinal Ganglion Cell Degeneration and Apoptosis Sustained ATP shortfall and oxidative stress lower the apoptotic threshold of retinal ganglion cells, driving their dysfunction and death.

Show evidence (4 references)

PMID:34311469 SUPPORT In Vitro

"decreased membrane potential, in addition to increased production of"

Cybrid measurements demonstrate the paired ATP/membrane-potential deficit and increased mitochondrial ROS that define this node.

PMID:34311469 SUPPORT In Vitro

"mutation mediated apoptosis, as evidenced by the elevated release of"

Links the bioenergetic/oxidative lesion directly to apoptotic activation in mutation-bearing cells.

PMID:18427623 PARTIAL In Vitro

"LHON mtDNA mutations may interfere with superoxide regulation,"

The RGC-specific superoxide-dysregulation account is framed by the author as a hypothesis, and the underlying measurements were made in the RGC-5 line, later shown not to be of retinal ganglion cell origin; recorded as PARTIAL for that reason.

+ 1 more reference

Retinal Ganglion Cell Degeneration and Apoptosis

Retinal ganglion cells are the selectively vulnerable cell type in LHON and in mitochondrial optic neuropathies generally. Their long, partly unmyelinated intraretinal axons impose a high and spatially distributed energy demand that a complex-I-deficient mitochondrial population cannot sustain, and the cells die by apoptosis. Ganglion cell layer thinning on OCT can precede overt optic atrophy.

Retinal ganglion cell CL:0000740

neuron apoptotic process GO:0051402 ↑ INCREASED

retina UBERON:0000966

Downstream

Papillomacular Bundle Axonal Degeneration RGC death is not uniform across the ganglion cell population: the smallest-caliber axons, which constitute the papillomacular bundle serving central vision, are preferentially lost.

Show evidence (2 references)

PMID:19001017 SUPPORT Human Clinical

"The selective vulnerability of retinal ganglion cells (RGCs)"

Identifies selective RGC vulnerability as the key pathological feature of LHON.

PMID:38540197 SUPPORT Human Clinical

"oxidative stress, leading to the loss of retinal ganglion neurons and axons."

Places RGC and axon loss as the direct consequence of the mitochondrial/oxidative lesion.

Papillomacular Bundle Axonal Degeneration

Ultrastructural morphometry of LHON optic nerves shows 95-99% depletion of the nerve fiber population, with surviving fibers confined to the periphery and a marked loss of axons below 1 micron in diameter — the P-cell population that forms the papillomacular bundle. This anatomical selectivity is what converts a generalized bioenergetic defect into the characteristic clinical picture of dense central/centrocecal scotoma and dyschromatopsia with relative sparing of peripheral fields and pupillary responses.

Retinal ganglion cell CL:0000740

nerve fiber layer of retina UBERON:0001793 optic nerve UBERON:0000941

Downstream

Optic Atrophy and Irreversible Central Vision Loss Loss of the papillomacular bundle progresses from acute-phase RNFL swelling and disc hyperemia through temporal and then diffuse optic pallor, producing permanent severe central visual impairment.

Show evidence (3 references)

PMID:11190025 SUPPORT Human Clinical

"The total depletion of optic nerve fiber population in the 2 cases of"

Documents the magnitude of optic nerve fiber loss in molecularly confirmed LHON optic nerves.

PMID:11190025 SUPPORT Human Clinical

"showed a marked diminution of the first peak of axons of less than 1 micron in"

Quantifies the specific loss of sub-micron axon calibers underlying papillomacular bundle degeneration.

PMID:11190025 SUPPORT Human Clinical

"of the papillomacular bundle nerve fiber layer."

Links the stereotypical clinical presentation to loss of the papillomacular bundle nerve fiber layer.

Optic Atrophy and Irreversible Central Vision Loss

The clinical endpoint: bilateral, painless, subacute central visual failure with dense central or centrocecal scotoma, severe dyschromatopsia, and optic atrophy. Visual acuity commonly deteriorates to the level of legal blindness and then plateaus, and the loss is generally irreversible. Spontaneous recovery does occur and is genotype-dependent, being most frequent with m.14484T>C and least with m.11778G>A; the quoted recovery percentages vary widely between series and are not curated here (see `notes`).

optic nerve UBERON:0000941

Show evidence (2 references)

PMID:20301353 SUPPORT Human Clinical

"presents in young adults as bilateral, painless, subacute visual failure."

GeneReviews defines the clinical endpoint of the pathophysiological chain.

PMID:38540197 SUPPORT Human Clinical

"Loss of vision is rapid and severe, predominantly in young adults."

Characterizes the rapidity and severity of the visual endpoint and its age distribution.

Penetrance Modulation by Genetic Background and Environmental Triggers

LHON is not a deterministic monogenic disease. Most carriers of a primary mtDNA variant never lose vision; conversion is gated by additional factors that act on the bioenergetic threshold of the retinal ganglion cell. Three modifier classes are established. (1) mtDNA haplogroup background: risk of visual failure is higher for m.11778G>A on haplogroup J2 and for m.14484T>C on haplogroup J1, higher for m.3460G>A on haplogroup K, and significantly lower for m.11778G>A on haplogroup H, with MT-CYB substitutions offering a mechanistic explanation. (2) Sex: males are affected four to five times more often than females, an asymmetry not explicable by maternal transmission alone. (3) Environmental exposure: smoking is strongly and consistently associated with visual loss independent of sex and alcohol, with clinical penetrance reaching 93% in men who smoked; heavy alcohol intake shows a weaker trend. This node is the mechanistic bridge between genotype and the observed low penetrance (17.5% of males and 5.4% of females in a contemporary Australian registry cohort). Those two penetrance figures are not in conflict and must not be compared directly: the 93% figure is conditional on smoking and comes from LHON-affected pedigrees ascertained through probands, whereas the 17.5%/5.4% figures are unconditional lifetime risks from a registry that includes 4,948 largely asymptomatic carriers. The registry authors state explicitly that historically higher male rates are not supported by their data. The same ascertainment caveat separates the clinical carrier prevalence recorded under `prevalence` (11.82 per 100,000) from the population-genomic susceptibility estimate of roughly 1 in 1,000.

Retinal ganglion cell CL:0000740

Downstream

Retinal Ganglion Cell Degeneration and Apoptosis Modifier factors determine whether the underlying complex I defect crosses the threshold at which retinal ganglion cells decompensate and die, converting an asymptomatic carrier into an affected individual.

Show evidence (4 references)

PMID:17668373 SUPPORT Human Clinical

"haplogroup J (J2 for 11778G-->A and J1 for 14484T-->C) and when the 3460G-->A"

Establishes haplogroup J subclades as risk-raising backgrounds for two of the three primary variants.

PMID:17668373 SUPPORT Human Clinical

"significantly less when 11778G-->A occurs in haplogroup H."

Documents the protective haplogroup H background, the mirror image of the haplogroup J risk effect.

PMID:19525327 SUPPORT Human Clinical

"and alcohol intake, leading to a clinical penetrance of 93% in men who smoked."

Quantifies the dominant environmental modifier of penetrance.

+ 1 more reference

✶

Histopathology

2

Near-Total Optic Nerve Fiber Depletion with Peripheral Sparing

Light and electron microscopy of optic nerves from molecularly characterised LHON cases shows depletion of the nerve fiber population of 95-99%, with the few surviving fibers confined to the periphery of the nerve. This is the tissue-level correlate of the clinical optic atrophy.

Show evidence (1 reference)

PMID:11190025 SUPPORT Human Clinical

"LHON varied from 95% to 99%. Those fibers that were spared were limited to the"

Direct post-mortem morphometry quantifying the magnitude of fiber loss and the peripheral distribution of survivors.

Preferential Loss of Sub-Micron (P-Cell) Axons

Axon-caliber spectra generated from electron micrographs show a marked diminution of the first peak (axons under 1 micron in diameter) with relative emphasis of a second peak around 2 microns, indicating preferential loss of the smallest axons — the P-cell population that forms the papillomacular bundle — and relative preservation of the larger M-cell fibers. This is the histopathological basis for the clinical combination of dyschromatopsia and central scotoma with preserved pupillary responses.

Show evidence (2 references)

PMID:11190025 SUPPORT Human Clinical

"showed a marked diminution of the first peak of axons of less than 1 micron in"

Quantifies the selective loss of the smallest axon calibers on morphometry.

PMID:11190025 SUPPORT Human Clinical

"preferential loss of the smallest axons corresponding to the P-cell population."

Identifies the lost population as the P-cells that subserve central and colour vision.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

16

Eye 5

Subacute Bilateral Central Visual Loss VERY_FREQUENT Visual impairment HP:0000505

Temporal: SUBACUTE Course: PROGRESSIVE

Show evidence (2 references)

PMID:20301353 SUPPORT Human Clinical

"presents in young adults as bilateral, painless, subacute visual failure."

GeneReviews describes bilateral painless subacute visual failure as the typical presentation of affected individuals, supporting the VERY_FREQUENT band.

PMID:37071596 SUPPORT Human Clinical

"with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"

Confirms sudden severe vision loss as the defining acute-phase feature.

Central Scotoma Central scotoma HP:0000603

Show evidence (1 reference)

PMID:11190025 SUPPORT Human Clinical

"The clinical features of dyschromatopsia and central scotoma (with"

Names central scotoma as a core clinical feature and ties it to selective P-cell loss.

Dyschromatopsia Color vision defect HP:0000551

Show evidence (1 reference)

PMID:11190025 SUPPORT Human Clinical

"stereotypical presentation of dyschromatopsia, loss of central vision, and loss"

Names dyschromatopsia as part of the stereotypical LHON presentation.

Optic Atrophy Optic atrophy HP:0000648

Course: PROGRESSIVE

Show evidence (2 references)

PMID:38540197 PARTIAL Human Clinical

"oxidative stress, leading to the loss of retinal ganglion neurons and axons."

Supports loss of retinal ganglion neurons and their axons, which is the direct anatomical substrate of optic atrophy; the cited sentence does not itself use the term "optic atrophy", hence PARTIAL.

PMID:37071596 SUPPORT Human Clinical

"This is followed by a chronic phase of retinal nerve fibre layer loss, but"

Documents the chronic-phase retinal nerve fibre layer loss that constitutes established optic atrophy.

Severe Irreversible Reduction in Visual Acuity Reduced visual acuity HP:0007663

Course: PROGRESSIVE Severity: SEVERE

Show evidence (1 reference)

PMID:21788663 SUPPORT Human Clinical

"neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life."

Characterizes LHON as the most common mtDNA disorder causing irreversible blindness in young adult life, supporting both the severity and the irreversibility of the acuity loss.

Musculoskeletal 1

Myopathy Myopathy HP:0003198

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"peripheral neuropathy, nonspecific myopathy, and movement disorders have been"

GeneReviews lists nonspecific myopathy among the extraocular features enriched in LHON.

Nervous System 4

Peripheral Neuropathy Peripheral neuropathy HP:0009830

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"peripheral neuropathy, nonspecific myopathy, and movement disorders have been"

GeneReviews lists peripheral neuropathy among the extraocular features enriched in LHON.

Movement Disorder Abnormality of movement HP:0100022

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"peripheral neuropathy, nonspecific myopathy, and movement disorders have been"

GeneReviews lists movement disorders among the neurologic abnormalities reported more commonly in LHON than in the general population.

Ataxia Ataxia HP:0001251

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"extraocular neurologic features (ataxia, peripheral neuropathy, nonspecific"

GeneReviews names ataxia among the extraocular neurologic features of LHON warranting multidisciplinary management.

Multiple Sclerosis-Like Illness (Harding Disease) CNS demyelination HP:0007305

Show evidence (3 references)

PMID:20301353 SUPPORT Human Clinical

"population. Some individuals with LHON, usually women, may also develop a"

GeneReviews notes the female-predominant MS-like illness in LHON.

PMID:24198293 SUPPORT Human Clinical

"multiple episodes of visual loss, predominance for women, and"

Characterizes the distinctive clinical profile of the LHON-MS (Harding) phenotype.

PMID:24198293 SUPPORT Human Clinical

"There was no association between LHON mtDNA mutations and MS in a"

Supports this entry's framing that the LHON-MS co-occurrence is coincidental rather than genetically driven. The meta-analysis refutes a genetic association between LHON mtDNA variants and MS, but it does not refute the phenotype claim itself, which is that some individuals with LHON do develop an MS-like illness.

Other 6

Centrocecal Scotoma Centrocecal scotoma HP:0000576

Show evidence (1 reference)

PMID:11190025 PARTIAL Human Clinical

"of the papillomacular bundle nerve fiber layer."

Supports papillomacular bundle loss, the anatomical basis of the centrocecal field defect; the cited abstract names the central rather than centrocecal form explicitly.

Temporal Optic Disc Pallor Temporal optic disc pallor HP:0012511

Show evidence (1 reference)

PMID:11190025 PARTIAL Human Clinical

"correlates well with the fundus findings of early losses of the papillomacular"

The cited study documents early fundus loss of the papillomacular bundle, which enters the disc temporally and is the anatomical substrate of temporal-sector pallor. It does not itself report optic disc pallor, so this is recorded as PARTIAL support for the sector-specific phenotype rather than as a direct observation of it.

Peripapillary Telangiectatic Microangiopathy Retinal telangiectasia HP:0007763

Temporal: ACUTE

Show evidence (1 reference)

PMID:37071596 SUPPORT Human Clinical

"with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"

Names telangiectatic and tortuous peripapillary vessels as an acute-phase LHON sign.

Retinal Nerve Fiber Layer Swelling and Subsequent Thinning Abnormal retinal nerve fiber layer morphology HP:0020119

Show evidence (2 references)

PMID:37071596 SUPPORT Human Clinical

"vessels around the optic nerve and swelling of the retinal nerve fibre layer."

Documents acute-phase RNFL swelling.

PMID:37071596 SUPPORT Human Clinical

"This is followed by a chronic phase of retinal nerve fibre layer loss, but"

Documents the subsequent chronic-phase RNFL loss.

Postural Tremor Postural tremor HP:0002174

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"Neurologic abnormalities such as postural tremor,"

GeneReviews lists postural tremor among the neurologic abnormalities enriched in LHON.

Cardiac Pre-Excitation Ventricular preexcitation HP:0004309

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"Referral to a cardiologist for individuals with pre-excitation syndrome on"

GeneReviews documents pre-excitation syndrome as a recognised, actionable LHON finding.

🧬

Genetic Associations

5

MT-ND4 (m.11778G>A in MT-ND4 is the most frequent primary LHON mtDNA variant and generally carries the poorest prognosis for spontaneous visual recovery. )

Gene: MT-ND4 hgnc:7459 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:37071596 SUPPORT Human Clinical

"mutations in ND1, ND4 and ND6, respectively."

Assigns m.11778G>A to the ND4 subunit gene.

MT-ND1 (m.3460G>A in MT-ND1 is one of the three primary LHON mtDNA variants; a de novo occurrence has been documented in a population-based cohort. )

Gene: MT-ND1 hgnc:7455 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:12518276 SUPPORT Human Clinical

"A de novo mtDNA mutation (G3460A) was"

Documents a de novo m.3460G>A event in a population-based LHON cohort.

MT-ND6 (m.14484T>C in MT-ND6 is the primary LHON variant with the most favourable natural history for spontaneous visual recovery. )

Gene: MT-ND6 hgnc:7462 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:37071596 SUPPORT Human Clinical

"mutations in ND1, ND4 and ND6, respectively."

Assigns m.14484T>C to the ND6 subunit gene.

DNAJC30 (Biallelic DNAJC30 variants — dominated by the p.Tyr51Cys founder allele in Central and Eastern European populations — cause autosomal recessive LHON and, less often, Leigh syndrome. )

Gene: DNAJC30 hgnc:16410 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:35148383 SUPPORT Human Clinical

"homozygous DNAJC30 p.Tyr51Cys founder variant, 24 manifesting with LHON, two"

Establishes the DNAJC30 p.Tyr51Cys founder allele as a recurrent cause of recessive LHON.

PMID:35148383 SUPPORT Human Clinical

"manifesting with Leigh syndrome, and two remaining asymptomatic."

Documents the Leigh syndrome arm of the DNAJC30 phenotype and the existence of asymptomatic homozygotes.

NQO1 (NQO1 is not a cause of LHON but a pharmacogenetic modifier of treatment response. Idebenone must be reduced by the cytosolic NAD(P)H oxidoreductase I (NQO1) before it can shuttle electrons to complex III; two polymorphic variants drastically reduce NQO1 protein levels in the homozygous or compound heterozygous state, which hampers that reduction. In a retrospective analysis of a large idebenone-treated LHON cohort, patients carrying those genotypes had the poorest therapy response, particularly on the m.3460G>A/MT-ND1 background. The authors frame this as grounds to *consider* NQO1 genotype alongside the mtDNA mutation, not as validated genotype-guided prescribing. )

Gene: NQO1 hgnc:2874 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (3 references)

PMID:38272025 SUPPORT Human Clinical

"or compound heterozygous NQO1 variants have the poorest therapy response, particularly if carrying the m.3460G>A/MT-ND1 LHON mutation."

Retrospective analysis of a large idebenone-treated LHON cohort, classified by therapy response, showing that patients homozygous or compound heterozygous for the NQO1 variants respond worst — the core clinical claim for treating NQO1 as a response modifier.

PMID:38272025 SUPPORT In Vitro

"two polymorphic variants drastically reduce NQO1 protein levels when homozygous or compound heterozygous. This hampers idebenone reduction."

Supplies the molecular mechanism linking NQO1 genotype to drug pharmacology: the variants lower NQO1 protein and thereby impair the reduction step idebenone depends on.

PMID:38272025 PARTIAL Human Clinical

"suggest consideration of patient NQO1 genotype and mitochondrial DNA mutation in the context of idebenone therapy."

The authors' own framing is that the findings "suggest consideration" of NQO1 genotype — supporting NQO1 as a candidate modifier while stopping short of establishing genotype-guided prescribing.

💊

Medical Actions

6

Idebenone

Action: Pharmacotherapy NCIT:C15986

Agent: idebenone CHEBI:31687

Idebenone is a short-chain benzoquinone/coenzyme Q10 analogue that, after NQO1-mediated reduction, can accept electrons and deliver them to complex III, partly bypassing the defective complex I while also limiting oxidative injury. It is the only disease-specific drug authorised for LHON (European Medicines Agency, under exceptional circumstances), given at 900 mg/day (300 mg three times daily). The pivotal RHODOS randomised placebo-controlled trial did not meet its primary endpoint but favoured idebenone in secondary analyses, particularly in patients with discordant visual acuities at baseline; the later externally controlled LEROS study met its primary endpoint and confirmed long-term efficacy in the subacute/dynamic and chronic phases, with effect size varying by disease phase and causative variant. Benefit is greatest when treatment begins within the first year of visual loss.

Mechanism Target:

BYPASSES Complex I Electron Transfer Deficiency — Reduced idebenone shuttles electrons directly to complex III, partially bypassing the mutant complex I block and restoring some downstream electron flux and ATP synthesis. The predicate is BYPASSES rather than INHIBITS because idebenone does not suppress the defect — it routes electrons around it via an alternative path.

Show evidence (10 references)

PMID:20301353 SUPPORT Human Clinical

"idebenone, particularly those treated within the first year of onset of visual"

GeneReviews states that visual benefit is seen particularly in those treated within the first year.

PMID:21788663 PARTIAL Human Clinical

"statistical significance in the intention to treat population."

The RHODOS primary endpoint was not met in the intention-to-treat population, so the randomized evidence is partial rather than definitive.

PMID:21788663 PARTIAL Human Clinical

"discordant visual acuities are the most likely to benefit from idebenone"

Identifies the subgroup in which the randomized trial found benefit, but the finding came from a post hoc interaction analysis after the prespecified primary endpoint failed, so it is hypothesis-generating rather than confirmatory.

+ 7 more references

Lenadogene Nolparvovec Gene Therapy

Action: Gene Therapy NCIT:C15238

Agent: lenadogene nolparvovec NCIT:C174939

Lenadogene nolparvovec (GS010, rAAV2/2-ND4) is a single intravitreal AAV2 vector delivering a nuclear-encoded, mitochondrially targeted wild-type ND4 (allotopic expression) for m.11778G>A/MT-ND4 LHON. Across the RESCUE, REVERSE, REFLECT, and RESTORE programme, sustained bilateral visual improvement was observed for up to five years with a good safety profile apart from intraocular inflammation. Interpretation is materially confounded: sham-injected fellow eyes improved to essentially the same degree as treated eyes, so the within-patient primary endpoints were not met. A nonhuman-primate study found transfer of viral vector DNA to the contralateral, non-injected eye, which offers a plausible mechanistic explanation for that bilateral effect but also removes the fellow eye as an independent control. Gene therapy is therefore promising but not established routine care.

Mechanism Target:

RESTORES Complex I Electron Transfer Deficiency — Allotopic expression of a nuclear-encoded, mitochondrially targeted wild-type ND4 transgene supplies functional ND4 protein to the mitochondrion, complementing the mutant mtDNA-encoded subunit and restoring complex I electron transfer. The predicate is RESTORES, not INHIBITS: the causal mtDNA mutation itself is neither removed nor edited and persists after treatment, so the therapy acts on the downstream functional deficiency rather than on the lesion.

Show evidence (7 references)

PMID:33298565 PARTIAL Human Clinical

"Unexpectedly, sustained visual improvement was observed in both"

Improvement in both treated and sham eyes means the trial cannot attribute the improvement to the vector, so this is partial rather than full support.

PMID:33298565 SUPPORT Model Organism

"the anterior segment, retina, and optic nerve of the contralateral noninjected"

Nonhuman primate biodistribution data support contralateral vector transfer as the mechanism of the bilateral effect.

PMID:33298565 PARTIAL Human Clinical

"subjects (68%) had a clinically relevant recovery in BCVA from baseline in at"

Quantifies the proportion achieving clinically relevant recovery at week 96, but this is a single-arm responder rate that includes sham-injected eyes and has no independent untreated comparator, so it cannot be attributed to the vector.

+ 4 more references

Avoidance of Smoking and Heavy Alcohol

Action: smoking cessation and trigger-avoidance counselling Ontology label: Smoking Cessation Intervention NCIT:C15372

The only intervention with a documented effect on penetrance is exposure avoidance. Individuals in whom a LHON-causing mtDNA variant has been identified should be strongly advised not to smoke and to moderate alcohol intake, avoiding binge-drinking episodes, and to avoid other putative triggers such as head trauma, industrial toxins, and drugs with mitochondrial toxic effects. The treatment is bound to the NCIT smoking cessation intervention term because smoking is the dominant and only well-evidenced modifiable trigger; alcohol moderation and other trigger-avoidance advice are delivered in the same counselling encounter but have no more specific NCIT clinical-action term.

Mechanism Target:

MODULATES Penetrance Modulation by Genetic Background and Environmental Triggers — Removing the dominant environmental trigger lowers the probability that a carrier crosses the retinal ganglion cell decompensation threshold. The predicate is MODULATES rather than INHIBITS because the target node bundles risk-raising and risk-lowering modifiers, so the intervention shifts the balance rather than suppressing the node outright.

Show evidence (2 references)

PMID:20301353 SUPPORT Human Clinical

"strongly advised not to smoke and to moderate alcohol intake, avoiding"

The GeneReviews Agents/Circumstances to Avoid recommendation for LHON carriers.

PMID:19525327 SUPPORT Human Clinical

"mutation should be strongly advised not to smoke and to moderate their alcohol"

The primary gene-environment study's own recommendation, derived from its penetrance data.

Low Vision Rehabilitation and Supportive Care

Action: Rehabilitation NCIT:C15315

Management is otherwise supportive: provision of visual aids, occupational rehabilitation, registration with social services, and psychological support. A multidisciplinary approach should be considered for individuals with extraocular neurologic features to minimise their functional consequences.

Show evidence (2 references)

PMID:20301353 SUPPORT Human Clinical

"remains mostly supportive, and includes provision of visual aids, occupational"

GeneReviews defines the supportive-care core of LHON management.

PMID:20301353 SUPPORT Human Clinical

"A multidisciplinary approach for those affected individuals with"

Supports multidisciplinary management of extraocular LHON-plus features.

Cardiology Referral for Pre-Excitation

Action: Supportive Care NCIT:C15747

Referral to a cardiologist is recommended for individuals found to have a pre-excitation syndrome on electrocardiogram; symptomatic individuals are treated per standard cardiology practice.

Show evidence (1 reference)

PMID:20301353 SUPPORT Human Clinical

"Referral to a cardiologist for individuals with pre-excitation syndrome on"

The GeneReviews management recommendation for cardiac pre-excitation in LHON.

Genetic Counselling and Cascade Testing

Action: Genetic Counseling NCIT:C15240

Counselling must explain strict maternal transmission for mtDNA LHON, the inability of affected males to transmit, the sex- and age-dependent incomplete penetrance, and the different (autosomal recessive) risks of arLHON. Because heteroplasmy means a maternal relative may not carry the variant, each maternal family member seeking risk advice should undergo molecular testing rather than being assumed to be a carrier. Once the maternal variant is known, prenatal testing and preimplantation genetic testing are technically possible, but counselling must be explicit that a positive prenatal result is hard to interpret — mutational load in amniocytes and chorionic villi may not reflect other fetal or adult tissues, and the presence of the variant does not predict whether, when, how severely, or how fast visual loss will occur.

Show evidence (3 references)

PMID:20301353 SUPPORT Human Clinical

"complicated by the sex- and age-dependent penetrance of the primary mtDNA"

GeneReviews identifies incomplete sex- and age-dependent penetrance as the central counselling challenge.

PMID:12518276 SUPPORT Human Clinical

"harbor the mtDNA mutation, highlighting the importance of molecular genetic"

Establishes why heteroplasmy makes per-individual molecular testing necessary for counselling.

PMID:20301353 PARTIAL Human Clinical

"accurate interpretation of a positive prenatal test result is difficult because the mtDNA mutational"

Supports the reproductive-counselling caveat: prenatal testing is available but a positive result is difficult to interpret, so the option is offered with explicit limitations rather than as a predictive test.

🌍

Environmental Factors

3

Tobacco Smoking

Smoking is the best-established modifiable determinant of whether a LHON mtDNA carrier converts to visual loss. In a multicentre study of 196 affected and 206 unaffected carriers from 125 pedigrees, smoking showed a strong and consistent association with visual loss independent of sex and alcohol intake, with clinical penetrance reaching 93% in men who smoked. Carriers should be strongly advised not to smoke.

Show evidence (3 references)

PMID:19525327 SUPPORT Human Clinical

"consistent association between visual loss and smoking, independent of gender"

Establishes the independent smoking-visual loss association in a large multicentre carrier cohort.

PMID:19525327 SUPPORT Human Clinical

"and alcohol intake, leading to a clinical penetrance of 93% in men who smoked."

Quantifies the magnitude of the smoking effect on penetrance.

PMID:20301353 SUPPORT Human Clinical

"strongly advised not to smoke and to moderate alcohol intake, avoiding"

GeneReviews translates the smoking association into an explicit avoidance recommendation for carriers.

Heavy Alcohol Intake

Alcohol shows a weaker and less certain relationship with conversion than smoking: only heavy intake was associated with a trend towards increased visual failure in the definitive gene-environment study. Carriers are advised to moderate alcohol and avoid binge drinking.

Show evidence (2 references)

PMID:19525327 PARTIAL Human Clinical

"There was a trend towards increased visual failure with alcohol, but only with a"

The association is a trend restricted to heavy intake, not a firm independent risk factor.

PMID:20301353 SUPPORT Human Clinical

"binge-drinking episodes."

GeneReviews advises carriers to avoid binge-drinking episodes.

Other Putative Mitochondrial-Toxic Exposures

GeneReviews advises that it is reasonable for carriers to avoid other putative environmental triggers of visual loss, including head trauma, industrial toxins, and drugs with mitochondrial toxic effects. These associations rest largely on case reports rather than controlled estimates.

Show evidence (1 reference)

PMID:20301353 PARTIAL Human Clinical

"putative environmental triggers for visual loss, such as head trauma, industrial"

GeneReviews frames these as putative triggers, warranting a PARTIAL rather than SUPPORT classification.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Leber Hereditary Optic Neuropathy:

Inflammatory Optic Neuritis

Overlapping Features The most frequent and most consequential misdiagnosis. LHON is commonly mistaken for inflammatory optic neuritis associated with multiple sclerosis, AQP4-NMOSD, or MOGAD, which delays appropriate treatment.

Distinguishing Features

LHON is painless, whereas inflammatory optic neuritis is typically painful on eye movement.
LHON shows peripapillary telangiectasia and RNFL pseudoedema without fluorescein leakage.
Early macular ganglion cell loss on OCT favours LHON.
Corticosteroids and plasma exchange treat inflammatory optic neuritis but not LHON.

Show evidence (2 references)

PMID:39364415 SUPPORT Human Clinical

"Misdiagnosis, often as inflammatory optic neuritis, delays treatment, compounded"

Names inflammatory optic neuritis as the dominant misdiagnosis and its clinical consequence.

PMID:39364415 SUPPORT Human Clinical

"considering clinical clues such as ocular pain, fundus appearance and visual"

Identifies ocular pain, fundus appearance, and visual recovery as the discriminating clues.

Autosomal Dominant Optic Atrophy

Overlapping Features The other common inherited optic neuropathy of young adults. Like LHON it is a mitochondrial disease of the retinal ganglion cell, but it is caused by nuclear OPA1 mutations rather than mtDNA complex I variants.

Distinguishing Features

Insidious, slowly progressive, bilaterally symmetric childhood-onset visual loss rather than subacute sequential loss.
Autosomal dominant transmission rather than strict maternal transmission.
Caused by nuclear OPA1 variants rather than primary mtDNA complex I variants.

Show evidence (2 references)

PMID:19001017 SUPPORT Human Clinical

"Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy"

Establishes DOA as the paired inherited mitochondrial optic neuropathy that must be distinguished from LHON.

PMID:19001017 SUPPORT Human Clinical

"families have mutations in the OPA1 gene, which codes for an inner mitochondrial"

Identifies the nuclear OPA1 aetiology that distinguishes DOA from mtDNA-driven LHON.

Toxic and Nutritional Optic Neuropathy

Overlapping Features Toxic and nutritional optic neuropathies both mimic LHON and may aggravate it, since they converge on the same papillomacular bundle. Occupational solvent exposure and mitochondrial-toxic drugs should be elicited in the history.

Distinguishing Features

An identifiable toxic exposure or nutritional deficiency is present.
No maternal pedigree of visual failure.
May improve when the exposure is removed or the deficiency corrected.
Molecular mtDNA testing resolves the distinction.

Show evidence (1 reference)

PMID:38540197 PARTIAL Human Clinical

"Here, we review recent knowledge of the extrinsic determinants of LHON"

Supports the overlap between environmental/toxic determinants and LHON expression that underlies this differential; the review does not itself perform the differential-diagnostic comparison.

🔬

Clinical Trials

4

NCT02774005 PHASE_IV COMPLETED

LEROS: an open-label, external natural-history-controlled study of long-term idebenone (Raxone) treatment in LHON, enrolling 199 treated patients against 372 matched natural-history controls over 24 months. LEROS met its primary endpoint.

Target Phenotypes: Visual impairment HP:0000505

Show evidence (2 references)

clinicaltrials:NCT02774005 SUPPORT Human Clinical

"LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone"

ClinicalTrials.gov record confirming the LEROS design and objective.

PMID:38428428 SUPPORT Human Clinical

"LEROS meets its primary endpoint and"

The published LEROS result.

NCT02652767 PHASE_III COMPLETED

RESCUE: randomised, double-masked, sham-controlled phase 3 trial of a single intravitreal GS010 (lenadogene nolparvovec) injection in 39 patients with m.11778G>A/MT-ND4 LHON and vision loss of 6 months or less. One eye received vector and the fellow eye sham.

Target Phenotypes: Visual impairment HP:0000505

Show evidence (1 reference)

clinicaltrials:NCT02652767 SUPPORT Human Clinical

"assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation when vision loss is present for six months or less"

ClinicalTrials.gov record confirming the RESCUE design, target genotype, and the 6-month treatment window.

NCT03293524 PHASE_III COMPLETED

REFLECT: randomised, double-masked, placebo-controlled phase 3 trial of bilateral intravitreal GS010 (lenadogene nolparvovec) in patients with m.11778G>A/MT-ND4 LHON and vision loss of up to one year, comparing bilateral active injection with active first-eye plus placebo fellow-eye treatment.

Target Phenotypes: Visual impairment HP:0000505

Show evidence (1 reference)

clinicaltrials:NCT03293524 SUPPORT Human Clinical

"assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year"

ClinicalTrials.gov record confirming the REFLECT design, target genotype, and the one-year treatment window.

NCT03406104 PHASE_III COMPLETED

RESTORE: five-year long-term follow-up of the RESCUE and REVERSE phase 3 trials of GS010 (lenadogene nolparvovec) intravitreal gene therapy in m.11778G>A/MT-ND4 LHON, assessing durability of visual improvement, safety, and vision-related quality of life.

Target Phenotypes: Visual impairment HP:0000505

Show evidence (2 references)

clinicaltrials:NCT03406104 SUPPORT Human Clinical

"assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON"

ClinicalTrials.gov record confirming the RESTORE long-term follow-up design.

PMID:39699886 SUPPORT Human Clinical

"lenadogene nolparvovec demonstrated a sustained bilateral improvement in BCVA"

The published five-year RESTORE outcome.

{ }

Source YAML

click to show

name: Leber Hereditary Optic Neuropathy
creation_date: "2026-08-01T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: Leber hereditary optic neuropathy
  term:
    id: MONDO:0010788
    label: Leber hereditary optic neuropathy
description: >
  Leber hereditary optic neuropathy (LHON) is the prototypical maternally
  inherited mitochondrial DNA (mtDNA) disease: missense point mutations in
  mtDNA-encoded subunits of respiratory-chain complex I — most commonly
  m.11778G>A (MT-ND4), m.3460G>A (MT-ND1), and m.14484T>C (MT-ND6) — impair
  NADH-to-ubiquinone electron transfer, reducing ATP output and perturbing
  redox/superoxide handling. The consequence is remarkably tissue-restricted:
  retinal ganglion cells (RGCs), and preferentially the smallest-caliber
  P-cell axons of the papillomacular bundle, undergo bioenergetic failure and
  apoptosis, producing subacute, painless, bilateral (usually sequential)
  central visual loss in otherwise healthy young adults, followed by
  irreversible optic atrophy. Two features dominate the genetics and set LHON
  apart from a simple Mendelian model. First, penetrance is strikingly
  incomplete and sex-biased — most carriers never lose vision, and males are
  affected several-fold more often than females — so a pathogenic mtDNA
  genotype is emphatically not equivalent to disease. Second, this penetrance
  gap is only partly filled by established modifiers: mtDNA haplogroup
  background (haplogroup J subclades raise risk for m.11778G>A and
  m.14484T>C; haplogroup H lowers it for m.11778G>A), sex, and above all
  environmental triggers, with tobacco smoking the best-established
  modifiable risk factor and heavy alcohol a secondary one. An additional
  nuclear-genetic contribution is widely suspected but remains unresolved and
  is recorded here as an open knowledge gap rather than an asserted
  mechanism. A phenocopying
  autosomal recessive form (arLHON) caused by biallelic nuclear variants —
  most notably the DNAJC30 p.Tyr51Cys founder allele in Central/Eastern
  Europe, and also NDUFS2, MCAT, and NDUFA12 — has broken the historical
  dogma that all LHON is maternally transmitted. Idebenone, a short-chain
  quinone that bypasses complex I, is the only authorised disease-specific
  drug (EMA, exceptional circumstances); intravitreal allotopic MT-ND4 gene
  therapy (lenadogene nolparvovec) has shown sustained bilateral visual
  improvement but its trials were confounded by contralateral-eye improvement
  after unilateral injection. LHON must not be confused with Leber congenital
  amaurosis, a mechanistically unrelated early-onset retinal dystrophy.
synonyms:
- LHON
- Leber optic atrophy
- Leber hereditary optic atrophy
- optic atrophy, Leber type
parents:
- Hereditary Optic Neuropathy
- Mitochondrial Disease

references:
- reference: PMID:20301353
  title: "Leber Hereditary Optic Neuropathy."
  tags:
  - GeneReviews

inheritance:
- name: Mitochondrial inheritance
  description: >
    Classical LHON is caused by pathogenic variants in the mitochondrial
    genome and is transmitted exclusively down the maternal line. An affected
    or carrier woman transmits the variant to all of her offspring; an
    affected man transmits it to none. Most carriers are homoplasmic, but
    heteroplasmy occurs in a minority and means that a maternal relative of a
    proband may not carry the variant at all — molecular testing of each
    at-risk relative is therefore required rather than assumed transmission.
    Penetrance is incomplete and both sex- and age-dependent.
  inheritance_term:
    preferred_term: Mitochondrial inheritance
    term:
      id: HP:0001427
      label: Mitochondrial inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transmitted strictly by maternal inheritance."
    explanation: GeneReviews states that LHON mtDNA variants are transmitted strictly maternally.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "variant cannot transmit the variant to any of his offspring."
    explanation: Confirms that affected or carrier males do not transmit the mtDNA variant, the defining asymmetry of maternal inheritance.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complicated by the sex- and age-dependent penetrance of the primary mtDNA"
    explanation: Establishes that penetrance is both sex- and age-dependent, not complete.
  - reference: PMID:12518276
    reference_title: "The epidemiology of Leber hereditary optic neuropathy in the North East of England."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "but heteroplasmy was detected in approximately 12% of individuals."
    explanation: Quantifies the minority of LHON carriers who are heteroplasmic rather than homoplasmic.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In approximately 60% of families, a history of visual loss affecting maternal"
    explanation: >-
      Only about 60% of families show a visual-loss history in maternal
      relatives, so the absence of an obvious maternal pedigree does not
      exclude LHON — an important qualifier on the maternal-inheritance model.
- name: Autosomal recessive
  description: >
    A clinically indistinguishable autosomal recessive form (arLHON,
    OMIM 619382) is caused by biallelic variants in nuclear genes encoding
    complex I subunits or assembly/maintenance factors — DNAJC30 (the
    p.Tyr51Cys founder allele, prevalent in Central and Eastern Europe),
    NDUFS2, MCAT, and NDUFA12. arLHON should be considered whenever the LHON
    phenotype is convincing but mtDNA testing is unrevealing. Notably, arLHON
    retains the same male predominance and incomplete penetrance as
    mtDNA-driven LHON.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  penetrance: INCOMPLETE
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recently, biallelic mutations in the NDUFS2, DNAJC30, MCAT and NDUFA12 nuclear"
    explanation: Identifies the nuclear genes whose biallelic variants define autosomal recessive LHON.
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The discovery of arLHON cases breaks with the dogma of exclusive"
    explanation: States explicitly that arLHON overturns the assumption of exclusively maternal inheritance.
  - reference: PMID:35148383
    reference_title: "DNAJC30 defect: a frequent cause of recessive Leber hereditary optic neuropathy and Leigh syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "of unreported variant carriers confirms sex-dependent incomplete penetrance of"
    explanation: Shows that arLHON shares the sex-dependent incomplete penetrance of the mtDNA form.

has_subtypes:
- name: MT-ND4
  display_name: "m.11778G>A (MT-ND4)"
  description: >
    Widely reported as the most frequent primary LHON mtDNA variant
    worldwide and as the one with the poorest natural prognosis for
    spontaneous visual recovery; both statements are the consensus clinical
    view rather than claims curated here against a quantitative source. It is
    the genotype targeted by lenadogene nolparvovec gene therapy and the
    genotype enrolled in the RESCUE, REVERSE, REFLECT and RESTORE trials.
    Risk of visual failure is increased on mtDNA haplogroup J2 and decreased
    on haplogroup H.
  genes:
  - preferred_term: MT-ND4
    term:
      id: hgnc:7459
      label: MT-ND4
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in ND1, ND4 and ND6, respectively."
    explanation: Assigns m.11778G>A to MT-ND4 among the three primary LHON mtDNA variants.
- name: MT-ND1
  display_name: "m.3460G>A (MT-ND1)"
  description: >
    The second classical primary LHON variant, affecting the MT-ND1 complex I
    subunit. Unlike m.11778G>A and m.14484T>C it is not preferentially found
    on a specific haplogroup background, although risk is increased when it
    occurs on haplogroup K.
  genes:
  - preferred_term: MT-ND1
    term:
      id: hgnc:7455
      label: MT-ND1
  evidence:
  - reference: PMID:17668373
    reference_title: "Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutation is present in haplogroup K. By contrast, the risk of visual failure is"
    explanation: Documents the haplogroup K risk background specific to the m.3460G>A subtype.
- name: MT-ND6
  display_name: "m.14484T>C (MT-ND6)"
  description: >
    Conventionally regarded as the primary LHON variant with the highest rate
    of spontaneous visual recovery, and reported to be enriched in some
    founder populations (notably French-Canadian pedigrees); both are the
    consensus clinical view rather than claims curated here against a
    quantitative source. Its risk of visual failure is increased on mtDNA
    haplogroup J1.
  genes:
  - preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  evidence:
  - reference: PMID:17668373
    reference_title: "Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haplogroup J (J2 for 11778G-->A and J1 for 14484T-->C) and when the 3460G-->A"
    explanation: Assigns the J1 subclade risk background specifically to m.14484T>C.
- name: arLHON
  display_name: Autosomal Recessive LHON (DNAJC30 and other nuclear genes)
  subtype_term:
    preferred_term: Leber hereditary optic neuropathy, autosomal recessive
    term:
      id: MONDO:0030309
      label: Leber hereditary optic neuropathy, autosomal recessive
  description: >
    Nuclear-encoded, autosomal recessive phenocopy of classical LHON caused by
    biallelic DNAJC30, NDUFS2, MCAT, or NDUFA12 variants. The acute and chronic
    ocular course mirrors mtDNA LHON, but affected individuals have an earlier
    age of onset and a substantially higher rate of visual recovery, both
    spontaneous and idebenone-associated.
  genes:
  - preferred_term: DNAJC30
    term:
      id: hgnc:16410
      label: DNAJC30
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"
    explanation: Establishes that the arLHON clinical presentation copies that of mtDNA LHON.
  - reference: PMID:35148383
    reference_title: "DNAJC30 defect: a frequent cause of recessive Leber hereditary optic neuropathy and Leigh syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients demonstrate an earlier age of disease onset and a higher rate of"
    explanation: Documents the earlier onset and higher recovery rate distinguishing arLHON from the maternally inherited form.

pathophysiology:
- name: Complex I Subunit Missense Mutation
  biological_scale: MOLECULAR
  description: >
    The initiating lesion is a missense point mutation in a gene encoding a
    core subunit of respiratory-chain complex I (NADH:ubiquinone
    oxidoreductase). The large majority of molecularly resolved classical
    cases carry one of three usually homoplasmic mtDNA variants — m.11778G>A
    in MT-ND4, m.3460G>A in MT-ND1, or m.14484T>C in MT-ND6, which together
    are responsible for the majority of LHON cases worldwide. In arLHON the
    equivalent lesion is biallelic disruption of a nuclear complex I subunit
    or assembly/maintenance factor (DNAJC30, NDUFS2, MCAT, NDUFA12). Because
    mtDNA is present in every cell, the mutation itself is systemic; the
    disease phenotype is not.
  genes:
  - preferred_term: MT-ND4
    term:
      id: hgnc:7459
      label: MT-ND4
  - preferred_term: MT-ND1
    term:
      id: hgnc:7455
      label: MT-ND1
  - preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  - preferred_term: DNAJC30
    term:
      id: hgnc:16410
      label: DNAJC30
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  molecular_functions:
  - preferred_term: NADH dehydrogenase (ubiquinone) activity
    term:
      id: GO:0008137
      label: NADH dehydrogenase (ubiquinone) activity
    modifier: DECREASED
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in the mitochondrial genome, mainly the m.3460G>A, m.11778G>A and m.14484T>C"
    explanation: Names the three primary mtDNA variants that constitute the initiating lesion.
  - reference: PMID:34311469
    reference_title: "Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oxidoreductase (complex I) have been found to be responsible for the majority of LHON cases worldwide."
    explanation: Confirms that the three complex I subunit mutations account for the majority of LHON cases worldwide.
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in ND1, ND4 and ND6, respectively."
    explanation: Maps each primary variant to its complex I subunit gene.
  - reference: PMID:19001017
    reference_title: "Inherited mitochondrial optic neuropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations affecting the respiratory chain complexes"
    explanation: Identifies primary mtDNA mutations affecting respiratory chain complexes as the cause of LHON.
  downstream:
  - target: Complex I Electron Transfer Deficiency
    description: >
      Missense substitution of a core complex I subunit degrades assembly
      and/or catalytic function of the NADH:ubiquinone oxidoreductase
      holoenzyme, impairing electron transfer from NADH to ubiquinone.
    evidence:
    - reference: PMID:38540197
      reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "mitochondrial gene mutations that hinder oxidative phosphorylation and increase"
      explanation: States directly that the causal mitochondrial gene mutations hinder oxidative phosphorylation.

- name: Complex I Electron Transfer Deficiency
  biological_scale: MOLECULAR
  description: >
    Mutant complex I transfers electrons from NADH to ubiquinone
    inefficiently. Proton pumping across the inner membrane falls, the
    NADH/NAD+ redox couple shifts, and the coupled ATP-generating capacity of
    oxidative phosphorylation is reduced. The severity of the biochemical
    lesion is not uniform across the three primary variants: transmitochondrial
    cybrid work shows a frank assembly and catalytic-activity defect for
    m.3460G>A, whereas m.11778G>A and m.14484T>C are generally reported to
    impair coupling efficiency and raise ROS with comparatively better
    preserved catalytic activity, so this node should be read as a shared
    functional endpoint rather than an identical molecular block. Idebenone's
    therapeutic rationale is to accept electrons via NQO1 and deliver them
    downstream to complex III, partly bypassing this block.
  biological_processes:
  - preferred_term: mitochondrial electron transport, NADH to ubiquinone
    term:
      id: GO:0006120
      label: mitochondrial electron transport, NADH to ubiquinone
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: PMID:38540197
    reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mitochondrial gene mutations that hinder oxidative phosphorylation and increase"
    explanation: Directly links the mitochondrial gene mutations to impaired oxidative phosphorylation.
  - reference: PMID:34311469
    reference_title: "Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "manifested as defects in the assembly and activity of complex I, respiratory"
    explanation: Transmitochondrial cybrid experiments demonstrate the assembly and activity defect of complex I directly, the primary experimental evidence base for this node.
  - reference: PMID:34311469
    reference_title: "Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "deficiency, diminished mitochondrial adenosine triphosphate production, and"
    explanation: Cybrid data link the complex I defect to reduced mitochondrial ATP production, the coupled-output claim of this node.
  downstream:
  - target: ATP Deficit and Reactive Oxygen Species Overproduction
    description: >
      Reduced electron flux through complex I lowers ATP output while
      increasing electron leak, raising superoxide and downstream reactive
      oxygen species production.
    evidence:
    - reference: PMID:38540197
      reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "oxidative stress, leading to the loss of retinal ganglion neurons and axons."
      explanation: Connects the oxidative-stress consequence of the complex I defect to loss of retinal ganglion neurons.

- name: ATP Deficit and Reactive Oxygen Species Overproduction
  biological_scale: CELLULAR
  description: >
    The combination of a bioenergetic shortfall and increased electron leak
    creates chronic oxidative stress. Cybrid experiments show directly that
    the primary mutations raise mitochondrial ROS production while lowering
    ATP output and membrane potential, and that this is coupled to apoptotic
    activation (cytochrome c release, BAK/BAX, cleaved caspases) and impaired
    PINK1/parkin mitophagy. Why the resulting injury is confined to retinal
    ganglion cells remains unsettled. One proposed explanation is that RGCs
    regulate superoxide unusually tightly and that LHON mutations subvert
    that regulation — but the supporting measurement was made in the RGC-5
    cell line, which was subsequently shown not to be of retinal ganglion
    cell origin, so this should be treated as an unconfirmed hypothesis. The
    better-supported account of selective vulnerability is the anatomical one
    given in the downstream node: the long, partly unmyelinated intraretinal
    axon segment imposes an exceptionally high and spatially distributed ATP
    demand.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: reactive oxygen species metabolic process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
    modifier: INCREASED
  - preferred_term: ATP synthesis coupled electron transport
    term:
      id: GO:0042773
      label: ATP synthesis coupled electron transport
    modifier: DECREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:34311469
    reference_title: "Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "decreased membrane potential, in addition to increased production of"
    explanation: Cybrid measurements demonstrate the paired ATP/membrane-potential deficit and increased mitochondrial ROS that define this node.
  - reference: PMID:34311469
    reference_title: "Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "mutation mediated apoptosis, as evidenced by the elevated release of"
    explanation: Links the bioenergetic/oxidative lesion directly to apoptotic activation in mutation-bearing cells.
  - reference: PMID:18427623
    reference_title: "Mechanisms of retinal ganglion specific-cell death in Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "LHON mtDNA mutations may interfere with superoxide regulation,"
    explanation: The RGC-specific superoxide-dysregulation account is framed by the author as a hypothesis, and the underlying measurements were made in the RGC-5 line, later shown not to be of retinal ganglion cell origin; recorded as PARTIAL for that reason.
  - reference: PMID:18427623
    reference_title: "Mechanisms of retinal ganglion specific-cell death in Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "regulation of superoxide levels in RGCs would prevent aberrant apoptosis"
    explanation: States the proposed protective role of tight superoxide control; retained as a hypothesis rather than an established RGC property, given the cell-line provenance.
  downstream:
  - target: Retinal Ganglion Cell Degeneration and Apoptosis
    description: >
      Sustained ATP shortfall and oxidative stress lower the apoptotic
      threshold of retinal ganglion cells, driving their dysfunction and death.
    evidence:
    - reference: PMID:38540197
      reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "oxidative stress, leading to the loss of retinal ganglion neurons and axons."
      explanation: States the causal step from oxidative stress to loss of retinal ganglion neurons and their axons.

- name: Retinal Ganglion Cell Degeneration and Apoptosis
  biological_scale: CELLULAR
  description: >
    Retinal ganglion cells are the selectively vulnerable cell type in LHON
    and in mitochondrial optic neuropathies generally. Their long,
    partly unmyelinated intraretinal axons impose a high and spatially
    distributed energy demand that a complex-I-deficient mitochondrial
    population cannot sustain, and the cells die by apoptosis. Ganglion cell
    layer thinning on OCT can precede overt optic atrophy.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  evidence:
  - reference: PMID:19001017
    reference_title: "Inherited mitochondrial optic neuropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The selective vulnerability of retinal ganglion cells (RGCs)"
    explanation: Identifies selective RGC vulnerability as the key pathological feature of LHON.
  - reference: PMID:38540197
    reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oxidative stress, leading to the loss of retinal ganglion neurons and axons."
    explanation: Places RGC and axon loss as the direct consequence of the mitochondrial/oxidative lesion.
  downstream:
  - target: Papillomacular Bundle Axonal Degeneration
    description: >
      RGC death is not uniform across the ganglion cell population: the
      smallest-caliber axons, which constitute the papillomacular bundle
      serving central vision, are preferentially lost.
    evidence:
    - reference: PMID:11190025
      reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "preferential loss of the smallest axons corresponding to the P-cell population."
      explanation: Post-mortem optic-nerve morphometry demonstrates preferential loss of the smallest axons.

- name: Papillomacular Bundle Axonal Degeneration
  biological_scale: TISSUE
  description: >
    Ultrastructural morphometry of LHON optic nerves shows 95-99% depletion
    of the nerve fiber population, with surviving fibers confined to the
    periphery and a marked loss of axons below 1 micron in diameter — the
    P-cell population that forms the papillomacular bundle. This anatomical
    selectivity is what converts a generalized bioenergetic defect into the
    characteristic clinical picture of dense central/centrocecal scotoma and
    dyschromatopsia with relative sparing of peripheral fields and pupillary
    responses.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  locations:
  - preferred_term: nerve fiber layer of retina
    term:
      id: UBERON:0001793
      label: nerve fiber layer of retina
  - preferred_term: optic nerve
    term:
      id: UBERON:0000941
      label: cranial nerve II
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The total depletion of optic nerve fiber population in the 2 cases of"
    explanation: Documents the magnitude of optic nerve fiber loss in molecularly confirmed LHON optic nerves.
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed a marked diminution of the first peak of axons of less than 1 micron in"
    explanation: Quantifies the specific loss of sub-micron axon calibers underlying papillomacular bundle degeneration.
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "of the papillomacular bundle nerve fiber layer."
    explanation: Links the stereotypical clinical presentation to loss of the papillomacular bundle nerve fiber layer.
  downstream:
  - target: Optic Atrophy and Irreversible Central Vision Loss
    description: >
      Loss of the papillomacular bundle progresses from acute-phase RNFL
      swelling and disc hyperemia through temporal and then diffuse optic
      pallor, producing permanent severe central visual impairment.
    evidence:
    - reference: PMID:37071596
      reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "vessels around the optic nerve and swelling of the retinal nerve fibre layer."
      explanation: Describes the acute-phase RNFL swelling that precedes the chronic RNFL-loss phase.
  notes: >
    Ontology gap (UBERON new-term request candidate): there is no UBERON class
    for the **papillomacular bundle**, the specific arcuate fascicle of
    small-caliber retinal ganglion cell axons running from the macula to the
    temporal optic disc. Searches of the current UBERON release for
    "papillomacular", "maculopapillary", and "macular bundle" all return
    nothing. This node is therefore anchored on the two closest available
    parents — `UBERON:0001793` nerve fiber layer of retina and
    `UBERON:0000941` cranial nerve II — neither of which captures the
    sub-bundle whose selective loss is the defining anatomical lesion of LHON
    and of mitochondrial optic neuropathies generally. The same gap will
    affect any entry curating dominant optic atrophy, toxic/nutritional optic
    neuropathy, or other papillomacular-predominant disease, so a term request
    would have cross-entry value.

- name: Optic Atrophy and Irreversible Central Vision Loss
  biological_scale: ORGANISM
  description: >
    The clinical endpoint: bilateral, painless, subacute central visual
    failure with dense central or centrocecal scotoma, severe dyschromatopsia,
    and optic atrophy. Visual acuity commonly deteriorates to the level of
    legal blindness and then plateaus, and the loss is generally irreversible.
    Spontaneous recovery does occur and is genotype-dependent, being most
    frequent with m.14484T>C and least with m.11778G>A; the quoted recovery
    percentages vary widely between series and are not curated here (see
    `notes`).
  locations:
  - preferred_term: optic nerve
    term:
      id: UBERON:0000941
      label: cranial nerve II
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presents in young adults as bilateral, painless, subacute visual failure."
    explanation: GeneReviews defines the clinical endpoint of the pathophysiological chain.
  - reference: PMID:38540197
    reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss of vision is rapid and severe, predominantly in young adults."
    explanation: Characterizes the rapidity and severity of the visual endpoint and its age distribution.

- name: Penetrance Modulation by Genetic Background and Environmental Triggers
  biological_scale: ORGANISM
  description: >
    LHON is not a deterministic monogenic disease. Most carriers of a primary
    mtDNA variant never lose vision; conversion is gated by additional
    factors that act on the bioenergetic threshold of the retinal ganglion
    cell. Three modifier classes are established. (1) mtDNA haplogroup
    background: risk of visual failure is higher for m.11778G>A on haplogroup
    J2 and for m.14484T>C on haplogroup J1, higher for m.3460G>A on haplogroup
    K, and significantly lower for m.11778G>A on haplogroup H, with MT-CYB
    substitutions offering a mechanistic explanation. (2) Sex: males are
    affected four to five times more often than females, an asymmetry not
    explicable by maternal transmission alone. (3) Environmental exposure:
    smoking is strongly and consistently associated with visual loss
    independent of sex and alcohol, with clinical penetrance reaching 93% in
    men who smoked; heavy alcohol intake shows a weaker trend. This node is
    the mechanistic bridge between genotype and the observed low penetrance
    (17.5% of males and 5.4% of females in a contemporary Australian registry
    cohort). Those two penetrance figures are not in conflict and must not be
    compared directly: the 93% figure is conditional on smoking and comes
    from LHON-affected pedigrees ascertained through probands, whereas the
    17.5%/5.4% figures are unconditional lifetime risks from a registry that
    includes 4,948 largely asymptomatic carriers. The registry authors state
    explicitly that historically higher male rates are not supported by their
    data. The same ascertainment caveat separates the clinical carrier
    prevalence recorded under `prevalence` (11.82 per 100,000) from the
    population-genomic susceptibility estimate of roughly 1 in 1,000.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  evidence:
  - reference: PMID:17668373
    reference_title: "Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haplogroup J (J2 for 11778G-->A and J1 for 14484T-->C) and when the 3460G-->A"
    explanation: Establishes haplogroup J subclades as risk-raising backgrounds for two of the three primary variants.
  - reference: PMID:17668373
    reference_title: "Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "significantly less when 11778G-->A occurs in haplogroup H."
    explanation: Documents the protective haplogroup H background, the mirror image of the haplogroup J risk effect.
  - reference: PMID:19525327
    reference_title: "Gene-environment interactions in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and alcohol intake, leading to a clinical penetrance of 93% in men who smoked."
    explanation: Quantifies the dominant environmental modifier of penetrance.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "are four to five times more likely to be affected than females"
    explanation: States the sex bias that any penetrance model must explain.
  downstream:
  - target: Retinal Ganglion Cell Degeneration and Apoptosis
    description: >
      Modifier factors determine whether the underlying complex I defect
      crosses the threshold at which retinal ganglion cells decompensate and
      die, converting an asymptomatic carrier into an affected individual.
    evidence:
    - reference: PMID:19525327
      reference_title: "Gene-environment interactions in Leber hereditary optic neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "consistent association between visual loss and smoking, independent of gender"
      explanation: A modifier exposure (smoking) is directly associated with whether a carrier suffers visual loss, which is exactly the causal step asserted by this edge.
    - reference: PMID:38540197
      reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "that the incidence of genetic LHON susceptibility is around 1 in 1000, much"
      explanation: The carrier frequency greatly exceeding disease prevalence implies that factors beyond the primary variant gate conversion, but the figure itself speaks to prevalence rather than to the causal step, so this is partial support.

phenotypes:
- category: Ophthalmological
  name: Subacute Bilateral Central Visual Loss
  description: >
    Painless blurring of central vision in one eye, followed by the fellow eye
    within weeks to a few months. Acuity commonly deteriorates to worse than
    20/200 and reaches a nadir at around four months.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
    temporality: SUBACUTE
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presents in young adults as bilateral, painless, subacute visual failure."
    explanation: GeneReviews describes bilateral painless subacute visual failure as the typical presentation of affected individuals, supporting the VERY_FREQUENT band.
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"
    explanation: Confirms sudden severe vision loss as the defining acute-phase feature.
- category: Ophthalmological
  name: Central Scotoma
  description: >
    A dense central visual field defect corresponding to loss of the
    papillomacular bundle, often extending to involve the blind spot
    (centrocecal scotoma).
  phenotype_term:
    preferred_term: Central scotoma
    term:
      id: HP:0000603
      label: Central scotoma
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical features of dyschromatopsia and central scotoma (with"
    explanation: Names central scotoma as a core clinical feature and ties it to selective P-cell loss.
- category: Ophthalmological
  name: Centrocecal Scotoma
  description: >
    Extension of the central field defect to encompass the physiological
    blind spot, the classic field signature of papillomacular bundle disease.
  phenotype_term:
    preferred_term: Centrocecal scotoma
    term:
      id: HP:0000576
      label: Centrocecal scotoma
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "of the papillomacular bundle nerve fiber layer."
    explanation: Supports papillomacular bundle loss, the anatomical basis of the centrocecal field defect; the cited abstract names the central rather than centrocecal form explicitly.
- category: Ophthalmological
  name: Dyschromatopsia
  description: >
    Impaired colour discrimination, characteristically an early and prominent
    feature, reflecting preferential loss of the small P-cell axons that
    subserve colour vision.
  phenotype_term:
    preferred_term: Dyschromatopsia
    term:
      id: HP:0000551
      label: Color vision defect
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "stereotypical presentation of dyschromatopsia, loss of central vision, and loss"
    explanation: Names dyschromatopsia as part of the stereotypical LHON presentation.
- category: Ophthalmological
  name: Optic Atrophy
  description: >
    Chronic-phase optic nerve atrophy following the acute event, with
    permanent loss of the retinal nerve fiber layer.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38540197
    reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "oxidative stress, leading to the loss of retinal ganglion neurons and axons."
    explanation: Supports loss of retinal ganglion neurons and their axons, which is the direct anatomical substrate of optic atrophy; the cited sentence does not itself use the term "optic atrophy", hence PARTIAL.
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is followed by a chronic phase of retinal nerve fibre layer loss, but"
    explanation: Documents the chronic-phase retinal nerve fibre layer loss that constitutes established optic atrophy.
- category: Ophthalmological
  name: Temporal Optic Disc Pallor
  description: >
    Pallor first appears in the temporal sector of the optic disc, mirroring
    the temporal entry of the papillomacular bundle, and later becomes diffuse.
  phenotype_term:
    preferred_term: Temporal optic disc pallor
    term:
      id: HP:0012511
      label: Temporal optic disc pallor
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "correlates well with the fundus findings of early losses of the papillomacular"
    explanation: >-
      The cited study documents early fundus loss of the papillomacular bundle,
      which enters the disc temporally and is the anatomical substrate of
      temporal-sector pallor. It does not itself report optic disc pallor, so
      this is recorded as PARTIAL support for the sector-specific phenotype
      rather than as a direct observation of it.
- category: Ophthalmological
  name: Peripapillary Telangiectatic Microangiopathy
  description: >
    Telangiectatic, tortuous vessels around the optic disc are a
    characteristic acute-phase sign that, together with RNFL pseudoedema
    without fluorescein leakage, helps distinguish LHON from inflammatory
    optic neuritis.
  phenotype_term:
    preferred_term: Peripapillary retinal telangiectasia
    term:
      id: HP:0007763
      label: Retinal telangiectasia
    temporality: ACUTE
  diagnostic: true
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"
    explanation: Names telangiectatic and tortuous peripapillary vessels as an acute-phase LHON sign.
- category: Ophthalmological
  name: Retinal Nerve Fiber Layer Swelling and Subsequent Thinning
  description: >
    The peripapillary retinal nerve fiber layer thickens (pseudoedema) in the
    acute phase and then thins severely as axons are lost; macular ganglion
    cell layer thinning on OCT can precede symptoms.
  phenotype_term:
    preferred_term: Retinal nerve fiber layer swelling followed by thinning
    term:
      id: HP:0020119
      label: Abnormal retinal nerve fiber layer morphology
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vessels around the optic nerve and swelling of the retinal nerve fibre layer."
    explanation: Documents acute-phase RNFL swelling.
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is followed by a chronic phase of retinal nerve fibre layer loss, but"
    explanation: Documents the subsequent chronic-phase RNFL loss.
- category: Ophthalmological
  name: Severe Irreversible Reduction in Visual Acuity
  description: >
    Acuity commonly falls to or below the legal-blindness threshold and the
    loss is generally irreversible. Note that the deficit is a dense central
    one: peripheral fields and pupillary responses are relatively spared, so
    this is not total blindness and HP:0000618 (which implies a visual field
    no greater than 10 degrees around fixation) would be the wrong anchor.
  phenotype_term:
    preferred_term: Severe reduction in visual acuity to the legal-blindness threshold
    term:
      id: HP:0007663
      label: Reduced visual acuity
    severity: SEVERE
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:21788663
    reference_title: "A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life."
    explanation: Characterizes LHON as the most common mtDNA disorder causing irreversible blindness in young adult life, supporting both the severity and the irreversibility of the acuity loss.
- category: Neurological
  name: Postural Tremor
  description: >
    Postural tremor is reported more commonly in individuals with LHON than
    in the general population and is part of the extraocular "LHON-plus"
    spectrum.
  phenotype_term:
    preferred_term: Postural tremor
    term:
      id: HP:0002174
      label: Postural tremor
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic abnormalities such as postural tremor,"
    explanation: GeneReviews lists postural tremor among the neurologic abnormalities enriched in LHON.
- category: Neurological
  name: Peripheral Neuropathy
  description: >
    Peripheral neuropathy is part of the LHON-plus extraocular phenotype and
    is reported more often in LHON than in the general population.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "peripheral neuropathy, nonspecific myopathy, and movement disorders have been"
    explanation: GeneReviews lists peripheral neuropathy among the extraocular features enriched in LHON.
- category: Neurological
  name: Movement Disorder
  description: >
    Movement disorders occur as part of the LHON-plus spectrum in a minority
    of affected individuals. Deliberately anchored on the generic HPO class
    rather than on Dystonia: GeneReviews reports "movement disorders"
    generically, and LHON-plus dystonia is classically associated with
    different mtDNA variants (notably m.14459G>A, the Leigh-like
    LHON-dystonia phenotype) rather than with the three primary variants
    modelled in this entry.
  phenotype_term:
    preferred_term: Movement disorder
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "peripheral neuropathy, nonspecific myopathy, and movement disorders have been"
    explanation: GeneReviews lists movement disorders among the neurologic abnormalities reported more commonly in LHON than in the general population.
- category: Neurological
  name: Myopathy
  description: >
    Nonspecific myopathy is reported more commonly in individuals with LHON
    than in the general population and forms part of the LHON-plus
    extraocular spectrum.
  phenotype_term:
    preferred_term: Nonspecific myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "peripheral neuropathy, nonspecific myopathy, and movement disorders have been"
    explanation: GeneReviews lists nonspecific myopathy among the extraocular features enriched in LHON.
- category: Neurological
  name: Ataxia
  description: >
    Ataxia is one of the extraocular neurologic features for which
    GeneReviews recommends considering a multidisciplinary management
    approach in affected individuals.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "extraocular neurologic features (ataxia, peripheral neuropathy, nonspecific"
    explanation: GeneReviews names ataxia among the extraocular neurologic features of LHON warranting multidisciplinary management.
- category: Neurological
  name: Multiple Sclerosis-Like Illness (Harding Disease)
  description: >
    A subset of individuals with LHON, disproportionately women, develop a
    multiple sclerosis-like demyelinating illness. UK cohort and meta-analytic
    data indicate the co-occurrence is most likely coincidental rather than a
    genetic association, but the combined "Harding disease" phenotype is
    clinically distinct: multiple episodes of visual loss, a long interval to
    fellow-eye involvement, absent eye pain, and a poor visual prognosis.
  phenotype_term:
    preferred_term: Multiple sclerosis-like demyelinating illness
    term:
      id: HP:0007305
      label: CNS demyelination
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "population. Some individuals with LHON, usually women, may also develop a"
    explanation: GeneReviews notes the female-predominant MS-like illness in LHON.
  - reference: PMID:24198293
    reference_title: "Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "multiple episodes of visual loss, predominance for women, and"
    explanation: Characterizes the distinctive clinical profile of the LHON-MS (Harding) phenotype.
  - reference: PMID:24198293
    reference_title: "Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was no association between LHON mtDNA mutations and MS in a"
    explanation: >-
      Supports this entry's framing that the LHON-MS co-occurrence is
      coincidental rather than genetically driven. The meta-analysis refutes a
      genetic association between LHON mtDNA variants and MS, but it does not
      refute the phenotype claim itself, which is that some individuals with
      LHON do develop an MS-like illness.
- category: Cardiovascular
  name: Cardiac Pre-Excitation
  description: >
    Pre-excitation on the electrocardiogram (Wolff-Parkinson-White pattern)
    is recognised in LHON, and GeneReviews recommends cardiology referral for
    affected individuals in whom it is detected.
  phenotype_term:
    preferred_term: Cardiac pre-excitation
    term:
      id: HP:0004309
      label: Ventricular preexcitation
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Referral to a cardiologist for individuals with pre-excitation syndrome on"
    explanation: GeneReviews documents pre-excitation syndrome as a recognised, actionable LHON finding.

classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  mechanistic_category:
  - classification_value: mitochondrial disease

histopathology:
- name: Near-Total Optic Nerve Fiber Depletion with Peripheral Sparing
  description: >
    Light and electron microscopy of optic nerves from molecularly
    characterised LHON cases shows depletion of the nerve fiber population of
    95-99%, with the few surviving fibers confined to the periphery of the
    nerve. This is the tissue-level correlate of the clinical optic atrophy.
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LHON varied from 95% to 99%. Those fibers that were spared were limited to the"
    explanation: Direct post-mortem morphometry quantifying the magnitude of fiber loss and the peripheral distribution of survivors.
- name: Preferential Loss of Sub-Micron (P-Cell) Axons
  description: >
    Axon-caliber spectra generated from electron micrographs show a marked
    diminution of the first peak (axons under 1 micron in diameter) with
    relative emphasis of a second peak around 2 microns, indicating
    preferential loss of the smallest axons — the P-cell population that
    forms the papillomacular bundle — and relative preservation of the larger
    M-cell fibers. This is the histopathological basis for the clinical
    combination of dyschromatopsia and central scotoma with preserved
    pupillary responses.
  diagnostic: false
  evidence:
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed a marked diminution of the first peak of axons of less than 1 micron in"
    explanation: Quantifies the selective loss of the smallest axon calibers on morphometry.
  - reference: PMID:11190025
    reference_title: "Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "preferential loss of the smallest axons corresponding to the P-cell population."
    explanation: Identifies the lost population as the P-cells that subserve central and colour vision.
  notes: >
    Based on ultrastructural study of two molecularly characterised LHON optic
    nerves; the sample is small, as is inevitable for post-mortem optic nerve
    material in a non-lethal disease.

genetic:
- name: MT-ND4
  gene_term:
    preferred_term: MT-ND4
    term:
      id: hgnc:7459
      label: MT-ND4
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: MT-ND4
  association: >
    m.11778G>A in MT-ND4 is the most frequent primary LHON mtDNA variant and
    generally carries the poorest prognosis for spontaneous visual recovery.
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in ND1, ND4 and ND6, respectively."
    explanation: Assigns m.11778G>A to the ND4 subunit gene.
- name: MT-ND1
  gene_term:
    preferred_term: MT-ND1
    term:
      id: hgnc:7455
      label: MT-ND1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: MT-ND1
  association: >
    m.3460G>A in MT-ND1 is one of the three primary LHON mtDNA variants; a de
    novo occurrence has been documented in a population-based cohort.
  evidence:
  - reference: PMID:12518276
    reference_title: "The epidemiology of Leber hereditary optic neuropathy in the North East of England."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A de novo mtDNA mutation (G3460A) was"
    explanation: Documents a de novo m.3460G>A event in a population-based LHON cohort.
- name: MT-ND6
  gene_term:
    preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: MT-ND6
  association: >
    m.14484T>C in MT-ND6 is the primary LHON variant with the most favourable
    natural history for spontaneous visual recovery.
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in ND1, ND4 and ND6, respectively."
    explanation: Assigns m.14484T>C to the ND6 subunit gene.
- name: DNAJC30
  gene_term:
    preferred_term: DNAJC30
    term:
      id: hgnc:16410
      label: DNAJC30
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: arLHON
  association: >
    Biallelic DNAJC30 variants — dominated by the p.Tyr51Cys founder allele in
    Central and Eastern European populations — cause autosomal recessive LHON
    and, less often, Leigh syndrome.
  evidence:
  - reference: PMID:35148383
    reference_title: "DNAJC30 defect: a frequent cause of recessive Leber hereditary optic neuropathy and Leigh syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "homozygous DNAJC30 p.Tyr51Cys founder variant, 24 manifesting with LHON, two"
    explanation: Establishes the DNAJC30 p.Tyr51Cys founder allele as a recurrent cause of recessive LHON.
  - reference: PMID:35148383
    reference_title: "DNAJC30 defect: a frequent cause of recessive Leber hereditary optic neuropathy and Leigh syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "manifesting with Leigh syndrome, and two remaining asymptomatic."
    explanation: Documents the Leigh syndrome arm of the DNAJC30 phenotype and the existence of asymptomatic homozygotes.
- name: NQO1
  gene_term:
    preferred_term: NQO1
    term:
      id: hgnc:2874
      label: NQO1
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  association: >
    NQO1 is not a cause of LHON but a pharmacogenetic modifier of treatment
    response. Idebenone must be reduced by the cytosolic NAD(P)H
    oxidoreductase I (NQO1) before it can shuttle electrons to complex III;
    two polymorphic variants drastically reduce NQO1 protein levels in the
    homozygous or compound heterozygous state, which hampers that reduction.
    In a retrospective analysis of a large idebenone-treated LHON cohort,
    patients carrying those genotypes had the poorest therapy response,
    particularly on the m.3460G>A/MT-ND1 background. The authors frame this as
    grounds to *consider* NQO1 genotype alongside the mtDNA mutation, not as
    validated genotype-guided prescribing.
  evidence:
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "or compound heterozygous NQO1 variants have the poorest therapy response, \nparticularly if carrying the m.3460G>A/MT-ND1 LHON mutation."
    explanation: >-
      Retrospective analysis of a large idebenone-treated LHON cohort,
      classified by therapy response, showing that patients homozygous or
      compound heterozygous for the NQO1 variants respond worst — the core
      clinical claim for treating NQO1 as a response modifier.
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "two polymorphic variants drastically reduce NQO1 protein levels when homozygous \nor compound heterozygous. This hampers idebenone reduction."
    explanation: >-
      Supplies the molecular mechanism linking NQO1 genotype to drug
      pharmacology: the variants lower NQO1 protein and thereby impair the
      reduction step idebenone depends on.
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "suggest consideration of patient NQO1 genotype and mitochondrial DNA mutation in \nthe context of idebenone therapy."
    explanation: >-
      The authors' own framing is that the findings "suggest consideration" of
      NQO1 genotype — supporting NQO1 as a candidate modifier while stopping
      short of establishing genotype-guided prescribing.

variants:
- name: m.11778G>A
  description: >
    Usually homoplasmic mtDNA missense substitution in MT-ND4, the most
    common primary LHON variant worldwide and the genotype targeted by
    lenadogene nolparvovec gene therapy.
  gene:
    preferred_term: MT-ND4
    term:
      id: hgnc:7459
      label: MT-ND4
  clinical_significance: PATHOGENIC
  type: single_nucleotide_variant
  sequence_length: 1
  synonyms:
  - G11778A
  - 11778G>A
  evidence:
  - reference: PMID:33298565
    reference_title: "Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 37 subjects carrying the m.11778G>A (MT-ND4) mutation and"
    explanation: Confirms the m.11778G>A/MT-ND4 assignment in a phase 3 clinical trial population.
- name: m.3460G>A
  description: >
    mtDNA missense substitution in MT-ND1; one of the three primary LHON
    variants. Risk of visual failure is increased on haplogroup K.
  gene:
    preferred_term: MT-ND1
    term:
      id: hgnc:7455
      label: MT-ND1
  clinical_significance: PATHOGENIC
  type: single_nucleotide_variant
  sequence_length: 1
  synonyms:
  - G3460A
  - 3460G>A
  evidence:
  - reference: PMID:21788663
    reference_title: "A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A,"
    explanation: Confirms m.3460G>A as a primary LHON-causing variant enrolled in the RHODOS trial.
- name: m.14484T>C
  description: >
    mtDNA missense substitution in MT-ND6; the primary LHON variant most
    associated with spontaneous visual recovery. Risk is increased on
    haplogroup J1.
  gene:
    preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  clinical_significance: PATHOGENIC
  type: single_nucleotide_variant
  sequence_length: 1
  synonyms:
  - T14484C
  - 14484T>C
  evidence:
  - reference: PMID:17668373
    reference_title: "Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the 11778G-->A or 14484T-->C mutations are present in specific subgroups of"
    explanation: Confirms m.14484T>C as a primary LHON variant with a haplogroup-dependent risk profile.
- name: DNAJC30 p.Tyr51Cys
  description: >
    Founder missense allele in the nuclear DNAJC30 gene, prevalent in Central
    and Eastern European populations. In the homozygous state it causes
    autosomal recessive LHON and, less commonly, Leigh syndrome, with
    sex-dependent incomplete penetrance.
  gene:
    preferred_term: DNAJC30
    term:
      id: hgnc:16410
      label: DNAJC30
  clinical_significance: PATHOGENIC
  type: single_nucleotide_variant
  sequence_length: 1
  synonyms:
  - Y51C
  evidence:
  - reference: PMID:35148383
    reference_title: "DNAJC30 defect: a frequent cause of recessive Leber hereditary optic neuropathy and Leigh syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "homozygous DNAJC30 p.Tyr51Cys founder variant, 24 manifesting with LHON, two"
    explanation: Characterizes the recurrent homozygous founder allele and its LHON phenotype.

environmental:
- name: Tobacco Smoking
  description: >
    Smoking is the best-established modifiable determinant of whether a LHON
    mtDNA carrier converts to visual loss. In a multicentre study of 196
    affected and 206 unaffected carriers from 125 pedigrees, smoking showed a
    strong and consistent association with visual loss independent of sex and
    alcohol intake, with clinical penetrance reaching 93% in men who smoked.
    Carriers should be strongly advised not to smoke.
  effect: Strongly increases the risk of conversion from asymptomatic carrier to visual loss
  evidence:
  - reference: PMID:19525327
    reference_title: "Gene-environment interactions in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "consistent association between visual loss and smoking, independent of gender"
    explanation: Establishes the independent smoking-visual loss association in a large multicentre carrier cohort.
  - reference: PMID:19525327
    reference_title: "Gene-environment interactions in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and alcohol intake, leading to a clinical penetrance of 93% in men who smoked."
    explanation: Quantifies the magnitude of the smoking effect on penetrance.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "strongly advised not to smoke and to moderate alcohol intake, avoiding"
    explanation: GeneReviews translates the smoking association into an explicit avoidance recommendation for carriers.
- name: Heavy Alcohol Intake
  description: >
    Alcohol shows a weaker and less certain relationship with conversion than
    smoking: only heavy intake was associated with a trend towards increased
    visual failure in the definitive gene-environment study. Carriers are
    advised to moderate alcohol and avoid binge drinking.
  effect: Possible modest increase in risk of conversion, restricted to heavy intake
  evidence:
  - reference: PMID:19525327
    reference_title: "Gene-environment interactions in Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "There was a trend towards increased visual failure with alcohol, but only with a"
    explanation: The association is a trend restricted to heavy intake, not a firm independent risk factor.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "binge-drinking episodes."
    explanation: GeneReviews advises carriers to avoid binge-drinking episodes.
- name: Other Putative Mitochondrial-Toxic Exposures
  description: >
    GeneReviews advises that it is reasonable for carriers to avoid other
    putative environmental triggers of visual loss, including head trauma,
    industrial toxins, and drugs with mitochondrial toxic effects. These
    associations rest largely on case reports rather than controlled estimates.
  effect: Plausible but weakly evidenced triggers of conversion
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "putative environmental triggers for visual loss, such as head trauma, industrial"
    explanation: GeneReviews frames these as putative triggers, warranting a PARTIAL rather than SUPPORT classification.

prevalence:
- population: North East England
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 3.22
  rate_low: 2.47
  rate_high: 3.97
  notes: >
    Minimum point prevalence of visual failure due to LHON in the first
    population-based study, covering 2,173,800 individuals.
  evidence:
  - reference: PMID:12518276
    reference_title: "The epidemiology of Leber hereditary optic neuropathy in the North East of England."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LHON within this population was 3.22 per 100,000 (95% CI 2.47-3.97 per 100,000),"
    explanation: Reports the minimum point prevalence of manifest LHON in a defined population.
- population: North East England
  measure_type: CARRIER_FREQUENCY
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 11.82
  rate_low: 10.38
  rate_high: 13.27
  notes: >
    Minimum point prevalence of primary LHON mtDNA mutations (carriers,
    affected and unaffected) in the same population — roughly 3.7-fold the
    prevalence of manifest visual failure, a direct measure of the penetrance
    gap.
  evidence:
  - reference: PMID:12518276
    reference_title: "The epidemiology of Leber hereditary optic neuropathy in the North East of England."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and the minimum point prevalence for mtDNA LHON mutations was 11.82 per 100,000"
    explanation: Reports the carrier-level prevalence of primary LHON mtDNA mutations.
- population: Australia
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.46
  notes: >
    Minimum prevalence of vision loss due to LHON in Australia in 2020,
    reported as one in 68,403 individuals (= 1.46 per 100,000), from a
    registry cohort of 96 pedigrees with 620 affected individuals.
  evidence:
  - reference: PMID:34670133
    reference_title: "Establishing risk of vision loss in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vision loss due to LHON in Australia in 2020 was one in 68,403 individuals."
    explanation: Provides a contemporary registry-based prevalence of manifest LHON.

progression:
- phase: Acute and subacute phase
  age_range: Typically 15-30 years, with onset from childhood to late adulthood
  notes: >
    Painless blurring and dyschromatopsia begin in one eye; the fellow eye
    follows within weeks to a few months. Fundus signs include disc hyperemia,
    peripapillary telangiectatic microangiopathy, and RNFL pseudoedema without
    fluorescein leakage. Visual acuity falls rapidly, usually reaching a nadir
    around four months, and most macular ganglion cell loss is complete within
    the first six months.
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an acute phase of sudden and severe vision loss, telangiectatic and tortuous"
    explanation: Defines the acute phase and its characteristic fundus signs.
  - reference: PMID:39364415
    reference_title: "Recognizing Leber's Hereditary Optic Neuropathy to avoid delayed diagnosis and misdiagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "onset is typically between 15 and 30 years, but variability exists."
    explanation: Establishes the peak onset window with acknowledged variability.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "of those who lose their vision doing so before age 50 years."
    explanation: Establishes the age distribution of onset across the affected population.
- phase: Chronic phase
  age_range: From approximately 12 months after symptom onset
  notes: >
    RNFL swelling gives way to progressive RNFL loss, temporal then diffuse
    optic disc pallor, and established optic atrophy with a stable severe
    central deficit. Delayed partial or (rarely) substantial recovery may
    still occur after a year, most often with the m.14484T>C genotype and in
    arLHON.
  evidence:
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is followed by a chronic phase of retinal nerve fibre layer loss, but"
    explanation: Defines the chronic RNFL-loss phase and the possibility of partial or full recovery.

diagnosis:
- name: Targeted mtDNA Testing for the Three Primary Variants
  description: >
    Molecular diagnosis rests on identifying one of the three common primary
    mtDNA variants in a proband with a consistent clinical history. This
    targeted test is the recommended first-line investigation; if it is
    negative and suspicion persists, comprehensive mtDNA sequencing with
    heteroplasmy-sensitive methods should follow, and then a nuclear
    inherited-optic-neuropathy panel including DNAJC30, NDUFS2, MCAT, and
    NDUFA12.
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "consistent clinical history and/or one of three common mitochondrial DNA (mtDNA)"
    explanation: GeneReviews defines the diagnostic basis of LHON.
  - reference: PMID:39364415
    reference_title: "Recognizing Leber's Hereditary Optic Neuropathy to avoid delayed diagnosis and misdiagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic testing for the three most common LHON mutations is recommended"
    explanation: Supports targeted testing of the three common variants as the recommended first step.
- name: Optical Coherence Tomography
  description: >
    Spectral-domain OCT of the peripapillary RNFL and macular ganglion cell
    layer documents acute-phase RNFL thickening followed by severe thinning,
    and can detect ganglion cell loss before overt optic atrophy. It is a key
    tool for early recognition of LHON and for avoiding misdiagnosis as
    inflammatory optic neuritis.
  evidence:
  - reference: PMID:39364415
    reference_title: "Recognizing Leber's Hereditary Optic Neuropathy to avoid delayed diagnosis and misdiagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "assists clinicians in early recognition of LHON and help avoiding misdiagnosis."
    explanation: Establishes the role of OCT in early recognition and avoidance of misdiagnosis.

differential_diagnoses:
- name: Inflammatory Optic Neuritis
  description: >
    The most frequent and most consequential misdiagnosis. LHON is commonly
    mistaken for inflammatory optic neuritis associated with multiple
    sclerosis, AQP4-NMOSD, or MOGAD, which delays appropriate treatment.
  distinguishing_features:
  - LHON is painless, whereas inflammatory optic neuritis is typically painful on eye movement.
  - LHON shows peripapillary telangiectasia and RNFL pseudoedema without fluorescein leakage.
  - Early macular ganglion cell loss on OCT favours LHON.
  - Corticosteroids and plasma exchange treat inflammatory optic neuritis but not LHON.
  evidence:
  - reference: PMID:39364415
    reference_title: "Recognizing Leber's Hereditary Optic Neuropathy to avoid delayed diagnosis and misdiagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Misdiagnosis, often as inflammatory optic neuritis, delays treatment, compounded"
    explanation: Names inflammatory optic neuritis as the dominant misdiagnosis and its clinical consequence.
  - reference: PMID:39364415
    reference_title: "Recognizing Leber's Hereditary Optic Neuropathy to avoid delayed diagnosis and misdiagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "considering clinical clues such as ocular pain, fundus appearance and visual"
    explanation: Identifies ocular pain, fundus appearance, and visual recovery as the discriminating clues.
- name: Autosomal Dominant Optic Atrophy
  description: >
    The other common inherited optic neuropathy of young adults. Like LHON it
    is a mitochondrial disease of the retinal ganglion cell, but it is caused
    by nuclear OPA1 mutations rather than mtDNA complex I variants.
  distinguishing_features:
  - Insidious, slowly progressive, bilaterally symmetric childhood-onset visual loss rather than subacute sequential loss.
  - Autosomal dominant transmission rather than strict maternal transmission.
  - Caused by nuclear OPA1 variants rather than primary mtDNA complex I variants.
  evidence:
  - reference: PMID:19001017
    reference_title: "Inherited mitochondrial optic neuropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy"
    explanation: Establishes DOA as the paired inherited mitochondrial optic neuropathy that must be distinguished from LHON.
  - reference: PMID:19001017
    reference_title: "Inherited mitochondrial optic neuropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "families have mutations in the OPA1 gene, which codes for an inner mitochondrial"
    explanation: Identifies the nuclear OPA1 aetiology that distinguishes DOA from mtDNA-driven LHON.
- name: Toxic and Nutritional Optic Neuropathy
  description: >
    Toxic and nutritional optic neuropathies both mimic LHON and may aggravate
    it, since they converge on the same papillomacular bundle. Occupational
    solvent exposure and mitochondrial-toxic drugs should be elicited in the
    history.
  distinguishing_features:
  - An identifiable toxic exposure or nutritional deficiency is present.
  - No maternal pedigree of visual failure.
  - May improve when the exposure is removed or the deficiency corrected.
  - Molecular mtDNA testing resolves the distinction.
  evidence:
  - reference: PMID:38540197
    reference_title: "The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we review recent knowledge of the extrinsic determinants of LHON"
    explanation: Supports the overlap between environmental/toxic determinants and LHON expression that underlies this differential; the review does not itself perform the differential-diagnostic comparison.

treatments:
- name: Idebenone
  description: >
    Idebenone is a short-chain benzoquinone/coenzyme Q10 analogue that, after
    NQO1-mediated reduction, can accept electrons and deliver them to complex
    III, partly bypassing the defective complex I while also limiting
    oxidative injury. It is the only disease-specific drug authorised for
    LHON (European Medicines Agency, under exceptional circumstances), given
    at 900 mg/day (300 mg three times daily). The pivotal RHODOS randomised
    placebo-controlled trial did not meet its primary endpoint but favoured
    idebenone in secondary analyses, particularly in patients with discordant
    visual acuities at baseline; the later externally controlled LEROS study
    met its primary endpoint and confirmed long-term efficacy in the
    subacute/dynamic and chronic phases, with effect size varying by disease
    phase and causative variant. Benefit is greatest when treatment begins
    within the first year of visual loss.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: idebenone
      term:
        id: CHEBI:31687
        label: idebenone
  target_mechanisms:
  - target: Complex I Electron Transfer Deficiency
    treatment_effect: BYPASSES
    description: >
      Reduced idebenone shuttles electrons directly to complex III, partially
      bypassing the mutant complex I block and restoring some downstream
      electron flux and ATP synthesis. The predicate is BYPASSES rather than
      INHIBITS because idebenone does not suppress the defect — it routes
      electrons around it via an alternative path.
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "idebenone, particularly those treated within the first year of onset of visual"
    explanation: GeneReviews states that visual benefit is seen particularly in those treated within the first year.
  - reference: PMID:21788663
    reference_title: "A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "statistical significance in the intention to treat population."
    explanation: The RHODOS primary endpoint was not met in the intention-to-treat population, so the randomized evidence is partial rather than definitive.
  - reference: PMID:21788663
    reference_title: "A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "discordant visual acuities are the most likely to benefit from idebenone"
    explanation: >-
      Identifies the subgroup in which the randomized trial found benefit, but
      the finding came from a post hoc interaction analysis after the
      prespecified primary endpoint failed, so it is hypothesis-generating
      rather than confirmatory.
  - reference: PMID:21788663
    reference_title: "A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Idebenone was safe and well tolerated."
    explanation: Supports the safety and tolerability of the 900 mg/day regimen.
  - reference: PMID:38428428
    reference_title: "Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "confirms the long-term efficacy of idebenone in the subacute/dynamic and chronic"
    explanation: LEROS met its primary endpoint and confirmed long-term efficacy across disease phases.
  - reference: PMID:38428428
    reference_title: "Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "efficacy and safety of idebenone treatment (900 mg/day) in patients with LHON up"
    explanation: Documents the 900 mg/day dose evaluated in the confirmatory study.
  - reference: PMID:37071596
    reference_title: "Autosomal recessive Leber hereditary optic neuropathy, a new neuro-ophthalmo-genetic paradigm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Idebenone treatment significantly improved vision recovery in DNAJC30-associated"
    explanation: Extends the idebenone benefit to the autosomal recessive DNAJC30 form.
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the cytosolic NAD(P)H oxidoreductase I (NQO1) and directly shuttles electrons to \nrespiratory complex III, bypassing complex I affected in LHON."
    explanation: >-
      States the mechanism of action underpinning the BYPASSES predicate on
      this treatment's target_mechanisms edge: reduced idebenone delivers
      electrons to complex III, routing around the defective complex I rather
      than inhibiting anything.
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "(LHON), promotes recovery of visual function in up to 50% of patients, but we"
    explanation: >-
      Quantifies the ceiling of idebenone benefit — recovery in up to half of
      patients — and frames the non-responder problem this entry records as an
      open pharmacogenetic question.
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In its oxidized \nform, idebenone inhibits complex I, decreasing respiratory function in cells."
    explanation: >-
      Important safety/mechanism caveat: when idebenone is not reduced (as in
      low-NQO1 states) its oxidized form actively inhibits complex I and
      lowers respiration, so failure to reduce the drug is potentially harmful
      rather than merely ineffective.
  notes: >
    LEROS is an externally (natural-history) controlled open-label study, not
    a contemporaneous randomised comparison; its effect estimates should be
    read with that limitation in mind. Response is also modified by NQO1
    genotype (see the NQO1 record under `genetic` and the
    `gap_lhon_nqo1_idebenone_pharmacogenetics` discussion): idebenone requires
    NQO1-mediated reduction, and in the unreduced oxidized state it inhibits
    complex I rather than bypassing it.
- name: Lenadogene Nolparvovec Gene Therapy
  description: >
    Lenadogene nolparvovec (GS010, rAAV2/2-ND4) is a single intravitreal
    AAV2 vector delivering a nuclear-encoded, mitochondrially targeted
    wild-type ND4 (allotopic expression) for m.11778G>A/MT-ND4 LHON. Across
    the RESCUE, REVERSE, REFLECT, and RESTORE programme, sustained bilateral
    visual improvement was observed for up to five years with a good safety
    profile apart from intraocular inflammation. Interpretation is materially
    confounded: sham-injected fellow eyes improved to essentially the same
    degree as treated eyes, so the within-patient primary endpoints were not
    met. A nonhuman-primate study found transfer of viral vector DNA to the
    contralateral, non-injected eye, which offers a plausible mechanistic
    explanation for that bilateral effect but also removes the fellow eye as
    an independent control. Gene therapy is therefore promising but not
    established routine care.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
    therapeutic_agent:
    - preferred_term: lenadogene nolparvovec
      term:
        id: NCIT:C174939
        label: Lenadogene Nolparvovec
  target_mechanisms:
  - target: Complex I Electron Transfer Deficiency
    treatment_effect: RESTORES
    description: >
      Allotopic expression of a nuclear-encoded, mitochondrially targeted
      wild-type ND4 transgene supplies functional ND4 protein to the
      mitochondrion, complementing the mutant mtDNA-encoded subunit and
      restoring complex I electron transfer. The predicate is RESTORES, not
      INHIBITS: the causal mtDNA mutation itself is neither removed nor
      edited and persists after treatment, so the therapy acts on the
      downstream functional deficiency rather than on the lesion.
  evidence:
  - reference: PMID:33298565
    reference_title: "Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Unexpectedly, sustained visual improvement was observed in both"
    explanation: Improvement in both treated and sham eyes means the trial cannot attribute the improvement to the vector, so this is partial rather than full support.
  - reference: PMID:33298565
    reference_title: "Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the anterior segment, retina, and optic nerve of the contralateral noninjected"
    explanation: Nonhuman primate biodistribution data support contralateral vector transfer as the mechanism of the bilateral effect.
  - reference: PMID:33298565
    reference_title: "Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "subjects (68%) had a clinically relevant recovery in BCVA from baseline in at"
    explanation: >-
      Quantifies the proportion achieving clinically relevant recovery at week
      96, but this is a single-arm responder rate that includes sham-injected
      eyes and has no independent untreated comparator, so it cannot be
      attributed to the vector.
  - reference: PMID:39699886
    reference_title: "Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lenadogene nolparvovec demonstrated a sustained bilateral improvement in BCVA"
    explanation: Establishes durability of the bilateral visual improvement to five years.
  - reference: PMID:39699886
    reference_title: "Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "nadir in at least 1 eye was observed in 66.1% of participants (41 of 62)."
    explanation: >-
      Quantifies the five-year responder rate measured from nadir, but this is
      an uncontrolled within-cohort improvement; the same paper reports no
      significant difference between lenadogene-treated and sham eyes at
      either two years (P = .60) or five years (P = .27).
  - reference: PMID:39699886
    reference_title: "Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "logMAR (+4 lines) for eyes treated with sham (difference, -0.05; 95% CI, -0.15"
    explanation: >-
      At five years the difference between lenadogene-treated and sham-treated
      eyes was not significant, refuting any claim of a demonstrated
      eye-level treatment effect in this trial design.
  - reference: PMID:39699886
    reference_title: "Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Between 2 and 5 years, intraocular inflammation was noted in 4 participants with"
    explanation: Documents intraocular inflammation as the principal safety signal of intravitreal vector administration.
- name: Avoidance of Smoking and Heavy Alcohol
  description: >
    The only intervention with a documented effect on penetrance is exposure
    avoidance. Individuals in whom a LHON-causing mtDNA variant has been
    identified should be strongly advised not to smoke and to moderate
    alcohol intake, avoiding binge-drinking episodes, and to avoid other
    putative triggers such as head trauma, industrial toxins, and drugs with
    mitochondrial toxic effects. The treatment is bound to the NCIT smoking
    cessation intervention term because smoking is the dominant and only
    well-evidenced modifiable trigger; alcohol moderation and other
    trigger-avoidance advice are delivered in the same counselling encounter
    but have no more specific NCIT clinical-action term.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: smoking cessation and trigger-avoidance counselling
    term:
      id: NCIT:C15372
      label: Smoking Cessation Intervention
  target_mechanisms:
  - target: Penetrance Modulation by Genetic Background and Environmental Triggers
    treatment_effect: MODULATES
    description: >
      Removing the dominant environmental trigger lowers the probability that
      a carrier crosses the retinal ganglion cell decompensation threshold.
      The predicate is MODULATES rather than INHIBITS because the target node
      bundles risk-raising and risk-lowering modifiers, so the intervention
      shifts the balance rather than suppressing the node outright.
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "strongly advised not to smoke and to moderate alcohol intake, avoiding"
    explanation: The GeneReviews Agents/Circumstances to Avoid recommendation for LHON carriers.
  - reference: PMID:19525327
    reference_title: "Gene-environment interactions in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutation should be strongly advised not to smoke and to moderate their alcohol"
    explanation: The primary gene-environment study's own recommendation, derived from its penetrance data.
- name: Low Vision Rehabilitation and Supportive Care
  description: >
    Management is otherwise supportive: provision of visual aids,
    occupational rehabilitation, registration with social services, and
    psychological support. A multidisciplinary approach should be considered
    for individuals with extraocular neurologic features to minimise their
    functional consequences.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "remains mostly supportive, and includes provision of visual aids, occupational"
    explanation: GeneReviews defines the supportive-care core of LHON management.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A multidisciplinary approach for those affected individuals with"
    explanation: Supports multidisciplinary management of extraocular LHON-plus features.
- name: Cardiology Referral for Pre-Excitation
  description: >
    Referral to a cardiologist is recommended for individuals found to have a
    pre-excitation syndrome on electrocardiogram; symptomatic individuals are
    treated per standard cardiology practice.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Referral to a cardiologist for individuals with pre-excitation syndrome on"
    explanation: The GeneReviews management recommendation for cardiac pre-excitation in LHON.
- name: Genetic Counselling and Cascade Testing
  description: >
    Counselling must explain strict maternal transmission for mtDNA LHON, the
    inability of affected males to transmit, the sex- and age-dependent
    incomplete penetrance, and the different (autosomal recessive) risks of
    arLHON. Because heteroplasmy means a maternal relative may not carry the
    variant, each maternal family member seeking risk advice should undergo
    molecular testing rather than being assumed to be a carrier. Once the
    maternal variant is known, prenatal testing and preimplantation genetic
    testing are technically possible, but counselling must be explicit that a
    positive prenatal result is hard to interpret — mutational load in
    amniocytes and chorionic villi may not reflect other fetal or adult
    tissues, and the presence of the variant does not predict whether, when,
    how severely, or how fast visual loss will occur.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complicated by the sex- and age-dependent penetrance of the primary mtDNA"
    explanation: GeneReviews identifies incomplete sex- and age-dependent penetrance as the central counselling challenge.
  - reference: PMID:12518276
    reference_title: "The epidemiology of Leber hereditary optic neuropathy in the North East of England."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "harbor the mtDNA mutation, highlighting the importance of molecular genetic"
    explanation: Establishes why heteroplasmy makes per-individual molecular testing necessary for counselling.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "accurate interpretation of a positive prenatal test result is difficult because the mtDNA mutational"
    explanation: >-
      Supports the reproductive-counselling caveat: prenatal testing is
      available but a positive result is difficult to interpret, so the option
      is offered with explicit limitations rather than as a predictive test.

clinical_trials:
- name: NCT02774005
  phase: PHASE_IV
  status: COMPLETED
  description: >
    LEROS: an open-label, external natural-history-controlled study of
    long-term idebenone (Raxone) treatment in LHON, enrolling 199 treated
    patients against 372 matched natural-history controls over 24 months.
    LEROS met its primary endpoint.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: clinicaltrials:NCT02774005
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone"
    explanation: ClinicalTrials.gov record confirming the LEROS design and objective.
  - reference: PMID:38428428
    reference_title: "Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LEROS meets its primary endpoint and"
    explanation: The published LEROS result.
- name: NCT02652767
  phase: PHASE_III
  status: COMPLETED
  description: >
    RESCUE: randomised, double-masked, sham-controlled phase 3 trial of a
    single intravitreal GS010 (lenadogene nolparvovec) injection in 39
    patients with m.11778G>A/MT-ND4 LHON and vision loss of 6 months or less.
    One eye received vector and the fellow eye sham.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: clinicaltrials:NCT02652767
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation when vision loss is present for six months or less"
    explanation: ClinicalTrials.gov record confirming the RESCUE design, target genotype, and the 6-month treatment window.
- name: NCT03293524
  phase: PHASE_III
  status: COMPLETED
  description: >
    REFLECT: randomised, double-masked, placebo-controlled phase 3 trial of
    bilateral intravitreal GS010 (lenadogene nolparvovec) in patients with
    m.11778G>A/MT-ND4 LHON and vision loss of up to one year, comparing
    bilateral active injection with active first-eye plus placebo fellow-eye
    treatment.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: clinicaltrials:NCT03293524
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year"
    explanation: ClinicalTrials.gov record confirming the REFLECT design, target genotype, and the one-year treatment window.
- name: NCT03406104
  phase: PHASE_III
  status: COMPLETED
  description: >
    RESTORE: five-year long-term follow-up of the RESCUE and REVERSE phase 3
    trials of GS010 (lenadogene nolparvovec) intravitreal gene therapy in
    m.11778G>A/MT-ND4 LHON, assessing durability of visual improvement,
    safety, and vision-related quality of life.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: clinicaltrials:NCT03406104
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON"
    explanation: ClinicalTrials.gov record confirming the RESTORE long-term follow-up design.
  - reference: PMID:39699886
    reference_title: "Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lenadogene nolparvovec demonstrated a sustained bilateral improvement in BCVA"
    explanation: The published five-year RESTORE outcome.

discussions:
- discussion_id: gap_lhon_penetrance_determinants
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >
    What determines which carriers of a primary LHON mtDNA variant convert to
    visual loss, and can conversion risk be predicted prospectively for an
    individual?
  attaches_to:
  - pathophysiology#Penetrance Modulation by Genetic Background and Environmental Triggers
  rationale: >
    Primary LHON susceptibility variants occur in roughly 1 in 1,000 people —
    far more common than manifest disease — and even the best-characterised
    modifiers (mtDNA haplogroup, sex, smoking) leave most of the variance in
    conversion unexplained. No validated biomarker predicts conversion, and
    contemporary registry estimates of lifetime risk (17.5% in males, 5.4% in
    females) are substantially lower than older textbook figures, which has
    direct consequences for genetic counselling and for powering prevention
    trials in asymptomatic carriers.
  proposed_experiments:
  - experiment_id: exp_lhon_carrier_conversion_cohort
    name: Prospective biomarker cohort of asymptomatic LHON mtDNA carriers
    description: >
      Follow a large multicentre cohort of asymptomatic primary-variant
      carriers with serial spectral-domain OCT (peripapillary RNFL, macular
      GCL), colour vision, contrast sensitivity, and electrophysiology
      (PERG/photopic negative response) to identify structural or functional
      changes that precede conversion, and estimate their positive predictive
      value for visual loss.
    experiment_type:
      preferred_term: prospective longitudinal biomarker cohort study
    decision_criterion: >
      Identification of a pre-conversion measure whose change predicts
      subsequent visual loss with clinically useful sensitivity and
      specificity.
    would_support:
    - Conversion is preceded by a detectable subclinical structural or functional decline that can be used to time intervention.
    would_refute:
    - Conversion is abrupt and unheralded by any measurable pre-clinical change, making carrier surveillance non-informative.
  - experiment_id: exp_lhon_nuclear_modifier_gwas
    name: Nuclear modifier association study in discordant carrier sibships
    description: >
      Perform genome-wide (or exome-wide) association and rare-variant burden
      testing on affected versus unaffected carriers drawn from the same
      pedigrees, matched for mtDNA haplogroup and smoking exposure, to
      identify nuclear loci that modulate conversion independently of the
      known mtDNA and environmental modifiers.
    experiment_type:
      preferred_term: within-family genetic modifier association study
    decision_criterion: >
      Replicated association of one or more nuclear loci with conversion after
      conditioning on haplogroup and smoking.
    would_support:
    - Nuclear genetic background is a material determinant of LHON penetrance.
    would_refute:
    - Residual penetrance variance is environmental or stochastic rather than nuclear-genetic.
  evidence:
  - reference: PMID:34670133
    reference_title: "Establishing risk of vision loss in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "previously-17.5% for males and 5.4% for females."
    explanation: Contemporary registry risk estimates are markedly lower than historical figures, underscoring the unresolved penetrance question.
  - reference: PMID:34670133
    reference_title: "Establishing risk of vision loss in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "women, older adults, and younger children are also at risk."
    explanation: Shows that the classic young-adult-male stereotype under-describes who is at risk, an open counselling problem.
- discussion_id: gap_lhon_gene_therapy_effect_identifiability
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >
    Does intravitreal allotopic MT-ND4 gene therapy produce a real treatment
    effect over natural history, given that sham-injected fellow eyes improved
    to the same degree as treated eyes?
  attaches_to:
  - pathophysiology#Complex I Subunit Missense Mutation
  rationale: >
    In RESCUE and REVERSE the within-patient design was invalidated by
    bilateral improvement after unilateral injection, plausibly explained by
    contralateral vector transfer demonstrated in nonhuman primates. Without
    an independent untreated control arm, the durable improvement observed to
    five years cannot be cleanly separated from spontaneous recovery. This is
    the central unresolved question for LHON gene therapy.
  proposed_experiments:
  - experiment_id: exp_lhon_gt_independent_control_trial
    name: Gene therapy trial with a between-patient untreated comparator
    description: >
      Run a randomised trial in which the comparator is an independent
      untreated (or rigorously matched external natural-history) group of
      patients rather than the fellow eye, stratified by genotype and time
      from symptom onset, so that the treatment effect is identifiable in the
      presence of contralateral vector spread.
    experiment_type:
      preferred_term: randomised controlled trial with between-patient comparator
    decision_criterion: >
      A statistically significant difference in best-corrected visual acuity
      between treated patients and the independent untreated comparator.
    would_support:
    - Allotopic ND4 gene therapy confers visual benefit beyond spontaneous recovery.
    would_refute:
    - The observed improvement reflects natural history rather than the vector.
  evidence:
  - reference: PMID:33298565
    reference_title: "Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unexpectedly, sustained visual improvement was observed in both"
    explanation: The bilateral improvement is precisely what makes the treatment effect unidentifiable in these trials.
  - reference: PMID:33298565
    reference_title: "Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "between the two treatment groups, was not met (P = 0.894)."
    explanation: The primary endpoint failure is a direct statement of the identifiability problem.
- discussion_id: gap_lhon_nqo1_idebenone_pharmacogenetics
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >
    Is NQO1 genotype a clinically actionable predictor of idebenone response
    in LHON?
  attaches_to:
  - pathophysiology#Complex I Electron Transfer Deficiency
  rationale: >
    Idebenone's mechanism requires NQO1-mediated reduction before it can
    shuttle electrons to complex III, so variants lowering NQO1 protein levels
    are a mechanistically coherent candidate explanation for non-response —
    and the unreduced, oxidized drug actively inhibits complex I, so the
    stakes are higher than simple inefficacy. Aleo et al. (2024) demonstrated
    both the molecular effect and a corresponding clinical signal, but the
    clinical arm was a retrospective analysis of an already-treated cohort
    rather than a prospective genotype-stratified trial, and the authors
    themselves put it no more strongly than "suggest consideration". Whether
    NQO1 genotype should actually gate or modify prescribing is unresolved.
  proposed_experiments:
  - experiment_id: exp_lhon_nqo1_stratified_idebenone_trial
    name: NQO1-genotype-stratified prospective idebenone trial
    description: >
      Prospectively stratify LHON patients starting idebenone by NQO1
      genotype/protein level and compare pre-specified visual-acuity response
      endpoints between strata, with paired measurement of NQO1 protein and
      idebenone reduction capacity in patient-derived cells.
    experiment_type:
      preferred_term: prospective pharmacogenetic stratified interventional study
    decision_criterion: >
      A clinically meaningful difference in idebenone response between
      low-NQO1 and normal-NQO1 strata.
    would_support:
    - NQO1 genotype should guide idebenone prescribing or dosing in LHON.
    would_refute:
    - NQO1 status does not usefully predict idebenone response, and non-response is driven by other factors.
  evidence:
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "can neither predict nor understand the non-responders."
    explanation: >-
      States the open problem this discussion records: idebenone
      non-responders can currently be neither predicted nor explained.
  - reference: PMID:38272025
    reference_title: "Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "suggest consideration of patient NQO1 genotype and mitochondrial DNA mutation in \nthe context of idebenone therapy."
    explanation: >-
      The proposed answer is offered as a consideration rather than a
      validated rule, which is precisely why this remains an open gap
      requiring a prospective stratified trial.

notes: >
  Scope and boundary notes. (1) This entry covers Leber hereditary optic
  neuropathy (MONDO:0010788, OMIM 535000) — the mtDNA complex I optic
  neuropathy. It is a completely different entity from Leber congenital
  amaurosis, an early-onset retinal dystrophy that shares only the eponym;
  dismech curates the latter separately (Leber_Congenital_Amaurosis_10,
  Leber_Congenital_Amaurosis_with_Early-Onset_Deafness). The NEC preflight
  against MONDO:0010788 (OMIM:535000, Orphanet:104, "mitochondrial oxidative
  phosphorylation disorder") was run before any deep-research content was
  used, and the Edison report was confirmed to be about the correct entity.
  (2) Autosomal dominant optic atrophy is the paired inherited mitochondrial
  optic neuropathy and is curated separately
  (Autosomal_Dominant_Optic_Atrophy_Plus, Behr_Syndrome); it is modelled here
  only as a differential diagnosis. (3) arLHON is curated as a subtype rather
  than a separate entry because its clinical phenotype and mechanism (a
  nuclear complex I lesion converging on the same RGC bioenergetic failure)
  copy classical LHON; MONDO:0030309 exists for it should a split later be
  preferred. (4) Deliberately omitted for lack of snippet-verifiable primary
  sources at curation time: quantitative genotype-specific spontaneous
  recovery rates, the Madrid capture-recapture prevalence figures, the
  Slovenian VFQ-25 quality-of-life and productivity-loss estimates, and the
  vitamin B12 deficiency association — all appeared in the Edison deep-research
  report but could not be traced to a citable abstract with an exact quotable
  snippet. The NQO1 idebenone-response modifier was previously on that list in
  error: PMID:38272025 is a real, quotable source and the claim is now fully
  evidenced on the NQO1 `genetic` record, the Idebenone treatment, and the
  `gap_lhon_nqo1_idebenone_pharmacogenetics` discussion. (5) Known ontology
  gap: UBERON has no papillomacular bundle class — see the notes on the
  "Papillomacular Bundle Axonal Degeneration" pathophysiology node.

📚

References & Deep Research

References

1

PMID:20301353

Leber Hereditary Optic Neuropathy.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Leber Hereditary Optic Neuropathy: Comprehensive Disease-Characteristics Report

Edison Scientific Literature 25 citations 2026-08-01T17:15:40.643572

Leber Hereditary Optic Neuropathy: Comprehensive Disease-Characteristics Report

Evidence scope. This report prioritizes peer-reviewed 2023–2024 literature, supplemented by landmark studies and current ClinicalTrials.gov records. Most information is aggregated disease-level evidence; the cited Madrid registry study used linked health records plus clinician-confirmed cases, while clinical trials and cohorts contain individual-participant observations. The report is not based on a single patient’s EHR.

Executive summary

Leber hereditary optic neuropathy (LHON) is an inherited mitochondrial neurodegenerative disorder characterized by selective loss of retinal ganglion cells (RGCs), producing rapid, painless, usually sequential bilateral central visual loss. Classical LHON is caused predominantly by one of three germline mitochondrial-DNA missense variants—m.11778G>A in MT-ND4, m.3460G>A in MT-ND1, and m.14484T>C in MT-ND6—which impair respiratory-chain complex I. Recently recognized, clinically similar autosomal-recessive forms result from biallelic nuclear variants, particularly in DNAJC30, and less commonly NDUFS2, NDUFA12, MCAT, and possibly other complex-I-associated genes. Incomplete, sex- and age-dependent penetrance means that carrying a pathogenic variant is not equivalent to developing optic neuropathy. (zeppieri2025isolatedandsyndromic pages 2-4, morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 2-4)

The upstream lesion is defective complex-I electron transfer; downstream consequences include impaired oxidative phosphorylation, reduced ATP reserve, excess reactive oxygen species, altered mitochondrial homeostasis, and apoptosis of metabolically vulnerable RGCs—especially small-caliber axons of the papillomacular bundle. This explains the characteristic central/centrocecal scotoma, dyschromatopsia, and eventual optic atrophy. (esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)

The principal disease-specific treatment is idebenone, authorized in Europe, commonly administered at 300 mg three times daily. Early and sufficiently prolonged therapy is favored. AAV2-mediated allotopic ND4 gene replacement has produced sustained bilateral improvements in trials, but contralateral improvement after unilateral injection complicates efficacy interpretation; it was not established routine clinical care in the 2023–2024 evidence base. (lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 4-5, NCT02652767 chunk 1, NCT03406104 chunk 1, NCT03293524 chunk 1)

domain	key facts	ontology/identifier suggestions	evidence/source
Disease definition	Primary inherited optic neuropathy causing rapid, painless, usually sequential bilateral central vision loss due to selective retinal ganglion cell degeneration and mitochondrial dysfunction	MONDO: MONDO:0010788; OMIM: 535000; MeSH: D029242 (“Optic Atrophy, Hereditary, Leber”); Category: Mendelian, mitochondrial; autosomal-recessive subtype noted separately	(OpenTargets Search: Leber hereditary optic neuropathy, esmaeil2023leber’shereditaryoptic pages 1-2, NCT01892943 chunk 1)
Disease identifiers / subtypes	Classical form is maternally inherited mtDNA disease; autosomal-recessive LHON also recognized	OMIM arLHON: 619382; MONDO arLHON: MONDO:0030309; “Leber-like hereditary optic neuropathy, autosomal recessive 1/2” MONDOs available via Open Targets context; ICD-10/ICD-11: uncertain—verify in OMIM/Orphanet/WHO	(OpenTargets Search: Leber hereditary optic neuropathy, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 1-2)
Synonyms	Leber hereditary optic neuropathy; Leber hereditary optic atrophy; hereditary optic atrophy, Leber type; LHON	Synonym curation term set; MeSH disease heading above	(NCT01892943 chunk 1, NCT02652767 chunk 1)
Causal genes / variants	>90–95% of cases due to three mtDNA missense variants affecting complex I: m.11778G>A (MT-ND4), m.3460G>A (MT-ND1), m.14484T>C (MT-ND6)	Genes: MT-ND4, MT-ND1, MT-ND6; variant class: missense, germline mtDNA; inheritance: mitochondrial	(esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 2-4)
Additional genetic causes	Nuclear autosomal-recessive LHON genes recently implicated: DNAJC30, NDUFS2, NDUFAF5; 2023 review also lists MCAT, NDUFA12 in unresolved LHON phenotype	OMIM gene IDs available for DNAJC30 618202, NDUFS2 612985, NDUFAF5 612360; inheritance: autosomal recessive	(lee2024hereditaryopticneuropathies pages 1-2, zeppieri2025isolatedandsyndromic pages 2-4)
Modifier biology	Incomplete penetrance; male bias; estrogen proposed as protective for mitochondrial function; treatment response may be modified by NQO1 levels	Modifier genes/factors: NQO1 (pharmacogenetic response modifier), sex-related hormonal effect; haplogroup/heteroplasmy details not fully resolved in gathered evidence	(lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)
Environmental risk factors	Smoking, excessive alcohol use, and toxic medications/exposures are advised against in carriers; environmental triggers modulate disease expression	CHEBI/Exposures: tobacco smoke uncertain CHEBI mapping here; ethanol CHEBI:16236 (verify if needed); exposure ontology terms uncertain—verify	(esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)
Protective / preventive factors	Avoid oxidative stressors; family screening/counseling; early recognition may enable treatment; vitamin B12 screening may be relevant in carriers because deficiency is enriched	Prevention annotations: cascade screening; genetic counseling; vitamin B12 monitoring (CHEBI:176843 cyanocobalamin class mapping uncertain)	(esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)
Core phenotype	Bilateral painless subacute central visual loss, often sequential; dyschromatopsia; dense central/centrocecal scotoma; poor acuity often worse than 20/200	HPO suggestions: central scotoma (HP term verify), decreased visual acuity (HP term verify), dyschromatopsia/color vision defect (HP term verify), optic atrophy (HP:0000648 likely, verify)	(zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 2-4, morgia2024recognizingleber’shereditary pages 1-2)
Fundus / structural ocular findings	Acute/subacute phase may show optic disc hyperemia, peripapillary telangiectasia, vascular tortuosity, RNFL swelling; chronic phase shows RNFL and ganglion cell thinning with temporal then diffuse optic pallor	HPO suggestions: optic disc pallor (verify), retinal nerve fiber layer thinning (verify), abnormality of color vision (verify)	(zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 2-4)
Disease stages / temporal development	Stages commonly described as asymptomatic carrier, subacute <6 months, dynamic 6–12 months, chronic >12 months; second eye usually affected within weeks to months	Temporal annotations for KB; onset: adolescent/young adult; pattern: subacute progressive bilateral sequential	(zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 2-4, iorga2025evaluationofvisual pages 1-2)
Age / sex distribution	Peak onset typically 15–30/35 years; onset can range from childhood to late adulthood; male predominance; penetrance estimates in gathered evidence range around 17.5% males, 5.4% females or older estimates 40–50% males, ~10% females	Demography fields: male-biased expression; age-at-onset = adolescent/young adult	(esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 2-4, morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2)
Epidemiology	Prevalence estimates vary by population: approximately 1/30,000 to 1/50,000 commonly cited; Madrid population study estimated 0.55/100,000 confirmed, 0.79/100,000 capture-recapture; susceptibility allele prevalence may be 1 in 800–1000	Epidemiology fields: prevalence, sex-stratified prevalence; disease rarity	(esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 1-2)
Extraocular / LHON-plus manifestations	Some patients have neurologic/systemic disease: dystonia, epilepsy, cerebellar ataxia, parkinsonism, myoclonus, peripheral neuropathy, encephalopathy; cardiac/endocrine dysfunction; overlap with multiple sclerosis (“Harding disease”)	HPO suggestions: ataxia (verify), peripheral neuropathy (verify), dystonia (verify); disease note: LHON-plus / Harding disease	(lee2024hereditaryopticneuropathies pages 2-4, layrolle2024theopticnerve pages 2-4)
Molecular mechanism	Primary lesion is complex I dysfunction in oxidative phosphorylation, reducing ATP generation and increasing reactive oxygen species; this initiates retinal ganglion cell dysfunction/apoptosis	GO suggestions: oxidative phosphorylation (GO:0006119), mitochondrial electron transport, NADH to ubiquinone (GO term verify), ATP synthesis coupled electron transport (GO:0042773 verify), reactive oxygen species metabolic process (GO:0072593 verify), apoptotic process (GO:0006915)	(layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)
Selective vulnerability	Preferential involvement of small axons in the papillomacular bundle serving central vision; degeneration extends along optic pathways	Anatomy/process links: papillomacular bundle anatomy term uncertain—verify; optic nerve degeneration	(zeppieri2025isolatedandsyndromic pages 2-4, layrolle2024theopticnerve pages 2-4)
Cell types involved	Primary affected cells are retinal ganglion cells and their axons; glial involvement/demyelination inferred in visual pathways on MRI/histopathology	CL suggestions: retinal ganglion cell (CL term verify); oligodendrocyte/astrocyte involvement secondary, verify	(esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 2-4)
Anatomy affected	Retina, retinal nerve fiber layer, ganglion cell layer, optic disc, optic nerve, optic chiasm/tracts, lateral geniculate nucleus, visual cortex	UBERON suggestions: retina (UBERON:0000966 likely, verify), optic nerve (UBERON term verify), optic chiasm (verify), lateral geniculate nucleus (verify), visual cortex (verify)	(layrolle2024theopticnerve pages 2-4)
Subcellular localization	Inner mitochondrial membrane / respiratory chain complex I are central sites of dysfunction	GO Cellular Component suggestions: mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), respiratory chain complex I (GO term verify)	(layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)
Diagnostic workflow	Clinical recognition plus targeted genetic testing for three common mtDNA variants first; if negative but suspicion persists, comprehensive mtDNA sequencing; consider nuclear arLHON genes if unresolved	Diagnostic concepts: targeted mtDNA testing; full mtDNA sequencing; nuclear gene panel incl. DNAJC30/NDUFS2/NDUFAF5 and others	(zeppieri2025isolatedandsyndromic pages 2-4, morgia2024recognizingleber’shereditary pages 1-2)
Diagnostic tests	Ophthalmic evaluation includes ETDRS visual acuity, OCT (RNFL/GCL changes), visual field testing with central/centrocecal scotoma, contrast sensitivity, color vision testing	LOINC-specific mappings not gathered; functional tests: OCT, Humphrey visual field, Pelli-Robson, Farnsworth-Munsell	(esmaeil2023leber’shereditaryoptic pages 1-2, NCT02652767 chunk 1, NCT02652767 chunk 2)
Differential diagnosis	Frequently misdiagnosed as inflammatory optic neuritis; also other optic neuropathies/toxic-metabolic causes should be excluded	Differential disease concepts: optic neuritis, NMOSD/MOGAD-related optic neuritis, toxic/nutritional optic neuropathy	(morgia2024recognizingleber’shereditary pages 1-2)
Prognosis / natural history	Visual acuity often plateaus by ~4 months at severe impairment; spontaneous recovery depends strongly on genotype, best with m.14484T>C; chronic deficits common	Prognosis fields: genotype-dependent recovery; early childhood onset may have better prognosis	(lee2024hereditaryopticneuropathies pages 2-4, catarino2017useofidebenone pages 5-6)
Variant-specific recovery	Spontaneous recovery estimates in gathered evidence: m.14484T>C up to 70% (or 37–71% in older review) vs m.11778G>A ~4–23% / ~15% and m.3460G>A ~15–25% / ~15%	Genotype–phenotype annotation	(morgia2024recognizingleber’shereditary pages 1-2, catarino2017useofidebenone pages 5-6)
Quality of life / burden	Vision-related QoL is markedly impaired; Slovenian 2024 patient study reported mean VFQ-25 = 30.4 (SD 12.9) and annual productivity loss EUR 11,608/person	Outcome concepts: VFQ-25 composite score; disability/productivity loss	(NCT03406104 chunk 1)
Standard treatment	Idebenone is the main approved disease-specific therapy in Europe; commonly dosed 300 mg three times daily (900 mg/day), usually for ≥1 year, ideally within 12 months of onset	NCIT suggestions: Idebenone (NCIT term verify); treatment class: antioxidant / quinone analog	(lee2024hereditaryopticneuropathies pages 2-4, catarino2017useofidebenone pages 5-6, zeppieri2025isolatedandsyndromic pages 13-14)
Idebenone evidence	RHODOS secondary endpoints favored idebenone; LEROS showed higher clinically relevant benefit at 12 months versus natural history cohort; longer treatment may improve chance of recovery	NCIT concept: pharmacologic intervention; pharmacogenetic modifier: NQO1 low-level variants associated with poorer response	(lee2024hereditaryopticneuropathies pages 4-5)
Gene therapy	Lenadogene nolparvovec / GS010 / rAAV2/2-ND4 studied in RESCUE, REVERSE, REFLECT, RESTORE; unilateral and bilateral intravitreal approaches investigated	NCIT suggestions: Gene Therapy (NCIT:C15238); Intravitreal Injection (NCIT term verify); vector: AAV2-based ND4 allotopic expression	(NCT02652767 chunk 1, NCT03406104 chunk 1, NCT03293524 chunk 1)
Gene-therapy trial details	RESCUE enrolled 39; RESTORE long-term follow-up enrolled 62; REFLECT enrolled 98; outcomes included BCVA, OCT GCL/RNFL, visual field, contrast sensitivity, color vision, QoL	ClinicalTrials.gov IDs: NCT02652767 (RESCUE), NCT03406104 (RESTORE), NCT03293524 (REFLECT)	(NCT02652767 chunk 1, NCT03406104 chunk 1, NCT03293524 chunk 1)
Supportive care	Visual rehabilitation and psychological support are recommended for all patients; counseling to avoid smoking/alcohol/toxic medications in carriers	NCIT suggestions: Rehabilitation (verify), Psychological Support (verify)	(lee2024hereditaryopticneuropathies pages 4-5)
Prevention / counseling	No established pharmacologic prophylaxis for unaffected carriers in gathered evidence; emphasize maternal inheritance/arLHON counseling, cascade testing, avoidance of triggers, and timely diagnosis	Genetic counseling; family screening; reproductive counseling	(esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)
Model systems	Cybrids, patient-derived fibroblasts, iPSC-derived retinal ganglion cells, and retinal organoids model LHON; models show increased RGC death, ATP/membrane-potential deficits, and rescue with correction or idebenone in some systems	Model annotations: in vitro cybrid, iPSC-RGC, retinal organoid; animal models mentioned but robust human-like models remain limited	(esmaeil2023leber’shereditaryoptic pages 1-2, zeppieri2025isolatedandsyndromic pages 13-14)
Model readouts / limitations	iPSC/cybrid-corrected systems help test causality and rescue; limitations include incomplete reproduction of whole visual pathway and scarcity of robust animal models for selective human RGC degeneration	Evidence type labels: human cell model, organoid, translational preclinical model	(zeppieri2025isolatedandsyndromic pages 13-14)

Table: This compact table organizes gathered Leber hereditary optic neuropathy facts into knowledge-base-ready domains, including identifiers, genetics, phenotypes, mechanisms, diagnostics, treatment, epidemiology, and models. Ontology and identifier fields are suggested conservatively, with uncertain IDs clearly marked for later verification.

1. Disease information

Definition and identifiers

LHON is a primary inherited optic neuropathy and mitochondrial disease causing acute/subacute degeneration of RGCs and the optic nerve.

MONDO: MONDO:0010788.
OMIM: #535000, LHON; autosomal-recessive LHON #619382.
MeSH: D029242, Optic Atrophy, Hereditary, Leber.
Autosomal-recessive MONDO entry: MONDO:0030309.
Orphanet: commonly indexed as ORPHA:104; this identifier should be validated against the current Orphanet release before production ingestion.
ICD: LHON is generally coded within hereditary optic atrophy/optic-nerve disorder categories rather than by a uniformly implemented disease-specific ICD-10 code. Country-specific mappings and the current ICD-11 browser should therefore be checked before deployment.

Open Targets associates MONDO:0010788 most strongly with MT-ND1, MT-ND4, MT-ND6 and other mitochondrial genes, and recognizes DNAJC30/NDUFS2 associations for autosomal-recessive LHON. (OpenTargets Search: Leber hereditary optic neuropathy, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 1-2, NCT01892943 chunk 1)

Synonyms: Leber hereditary optic neuropathy; Leber’s hereditary optic neuropathy; LHON; Leber hereditary optic atrophy; hereditary optic atrophy, Leber type. It must not be confused with Leber congenital amaurosis, a different retinal dystrophy.

2. Etiology, risk, and protective factors

Causal factors

Approximately 90–95% of molecularly resolved classical cases carry one of three mtDNA variants: m.11778G>A (MT-ND4; usually the most frequent), m.3460G>A (MT-ND1), or m.14484T>C (MT-ND6). These are germline, maternally transmitted missense variants, usually homoplasmic, affecting complex-I subunits. More than 50 rarer mtDNA variants have been reported, but pathogenicity requires careful evaluation because mtDNA variation is common. (morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 2-4)

Autosomal-recessive LHON phenocopies classical disease. DNAJC30 is particularly important in Eastern and Central European populations; biallelic NDUFS2, MCAT, NDUFA12, and reported NDUFAF5 defects should be considered when the phenotype is convincing but mtDNA testing is unrevealing. These discoveries overturn the older assumption that all LHON is maternally inherited. (zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 1-2)

Genetic susceptibility and modifiers

Penetrance is incomplete. Older estimates were approximately 40–50% in male and 10% in female carriers; more recent family data cited in 2024 guidance estimate 17.5% in males and 5.4% in females. Differences reflect ascertainment, genotype, age, ancestry, exposure, and family structure. Male predominance is not explained by mtDNA inheritance alone; estrogen-enhanced mitochondrial biogenesis and antioxidant defenses are a plausible protective mechanism, but not a clinically validated prophylaxis. (lee2024hereditaryopticneuropathies pages 2-4, morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 1-2)

Mitochondrial haplogroup, heteroplasmic load, nuclear background, and mitochondrial biogenesis influence expression, although no single modifier predicts conversion adequately. A clinically relevant 2024 development is evidence that variants lowering NQO1 protein can impair activation/effectiveness of idebenone, making NQO1 a candidate pharmacogenetic response modifier rather than a primary cause. (lee2024hereditaryopticneuropathies pages 4-5)

Environmental and lifestyle risks

Smoking is the best-supported modifiable risk factor. Heavy alcohol use is also associated with conversion, probably through oxidative stress, nutritional deficiency, and mitochondrial toxicity; the evidence for moderate alcohol is weaker. Other reported precipitating contexts include nutritional deficiency, severe illness, mitochondrial-toxic medicines, occupational toxins, and some antiretroviral, antitubercular, or toxic-optic-neuropathy drugs, but most drug associations rest on case reports rather than controlled estimates. There is no infectious cause and no zoonotic transmission. (esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)

A prospective cohort of 244 carriers/patients found vitamin-B12 deficiency in 21% of carriers younger than 65 versus 5–7% in the comparison population; excessive alcohol was a significant predictor. This does not prove that B12 deficiency triggers conversion, but supports periodic screening and correction.

Protective factors and gene–environment interaction

Recommended risk reduction consists of smoking abstinence, avoiding binge/heavy alcohol use, maintaining adequate nutrition—especially B12—and avoiding unnecessary mitochondrial/optic-nerve toxins. No medication has proven primary prophylactic efficacy in unaffected carriers. The conceptual interaction is: pathogenic complex-I genotype → reduced bioenergetic reserve → sex/nuclear/mtDNA-background modulation → environmental oxidative or nutritional stress → threshold crossing → RGC dysfunction and death. (layrolle2024theopticnerve pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)

3. Phenotypes

Core ocular phenotype

The typical patient is an otherwise healthy adolescent or young adult, often male, with painless blurring and impaired color vision in one eye, followed by the fellow eye within approximately 6–12 weeks or 2–3 months. Simultaneous bilateral onset occurs in roughly 25–50% in older series. Visual acuity frequently deteriorates to worse than 20/200, counting fingers, or poorer, with a dense central or centrocecal scotoma and markedly impaired contrast and color discrimination. Relative afferent pupillary asymmetry may be absent once disease is bilateral. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 2-4, morgia2024recognizingleber’shereditary pages 1-2)

Acute fundus signs include optic-disc hyperemia, circumpapillary telangiectatic microangiopathy, vascular tortuosity, and pseudoedema/RNFL swelling without typical fluorescein leakage. Macular ganglion-cell thinning can precede symptoms, while peripapillary RNFL initially thickens and then becomes severely thin. Chronic disease produces temporal and subsequently diffuse optic pallor. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 2-4)

Suggested HPO annotations: optic atrophy (HP:0000648); reduced visual acuity; central/centrocecal scotoma; color-vision defect/dyschromatopsia; painless visual loss; retinal nerve-fiber-layer thinning; optic-disc pallor; vascular tortuosity. Exact HPO identifiers other than HP:0000648 should be validated against the current HPO release.

Frequency, onset, severity, and progression

Peak onset is approximately 15–30 years; reported onset spans about 2–90 years, and around 10% may present after 50. Mean onset is approximately 25 years in males and 30 in females. Vision often reaches a nadir or plateau near four months. Most macular RGC loss is completed in the first six months, although anatomic degeneration may continue after functional stabilization. Childhood onset, especially before age 9–12, is less typical and often has a better prognosis. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 2-4)

LHON-plus

A minority develop extraocular disease—movement disorders, dystonia, tremor, parkinsonism, ataxia, epilepsy, myoclonus, peripheral neuropathy, myopathy, encephalopathy, cardiac conduction abnormalities, or endocrine dysfunction. Coexisting LHON and multiple-sclerosis-like disease is termed Harding disease and is reported disproportionately in women. In one cited imaging cohort, as many as 25% of 31 patients had MS-like T2 lesions, but causal overlap remains uncertain. (lee2024hereditaryopticneuropathies pages 2-4, layrolle2024theopticnerve pages 2-4)

Quality of life

Severe central visual loss impairs reading, driving, education, employment, facial recognition, and independent navigation, with substantial psychological effects. A 2024 Slovenian study of nine adults—one-third of known national cases—reported mean VFQ-25 of 30.4/100 (SD 12.9) and estimated annual productivity loss of €11,608 per affected person. Its small sample limits generalizability, but quantifies the major real-world burden.

4. Genetic and molecular information

Variant classes and population frequency

The three primary variants are germline mtDNA single-nucleotide missense substitutions. They are commonly homoplasmic, so a conventional nuclear-variant allele frequency is not directly applicable. Population genomic studies find primary LHON susceptibility variants in approximately 1/800–1/1,000 people—far more common than manifest disease—illustrating low penetrance and the danger of interpreting genotype without phenotype and pedigree. Heteroplasmic cases require quantification in blood and, if suspicion remains, another tissue because heteroplasmy may vary by tissue. (layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)

Nuclear arLHON variants are biallelic germline variants and can include missense, frameshift, nonsense, and splice-altering alleles. Classification should follow ACMG/AMP criteria with segregation, population frequency, phenotype, and functional evidence; ClinVar assertions must be reviewed variant by variant. Somatic mutation is not the usual etiology. Large chromosomal abnormalities, repeat expansions, aneuploidy, and translocations are not established causes, so karyotype, FISH, and chromosomal microarray are low-yield in a typical isolated LHON phenotype.

Epigenetics and omics

No validated disease-defining methylation, histone, or chromatin signature is used clinically. Transcriptomic work in patient-specific RGCs has implicated altered glutamatergic/AMPA-receptor signaling; cellular models also demonstrate abnormal mitochondrial transport, bioenergetics, apoptosis susceptibility, and mitophagy. These remain research findings rather than diagnostic biomarkers. Single-cell and spatial-transcriptomic human data are still limited, largely because affected retinal and optic-nerve tissue is inaccessible.

5. Environmental information

Tobacco smoke and heavy alcohol are the principal actionable exposures. Nutritional insufficiency, particularly B12 deficiency, may compound mitochondrial dysfunction. Occupational solvent/toxin exposure should be elicited because toxic optic neuropathy both mimics and may aggravate LHON. Radiation, pollution, and exercise have no established disease-specific causal estimates. There is no recognized bacterial, viral, fungal, or parasitic etiology. (esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2)

6. Mechanism and pathophysiology

Causal chain

Upstream genetic lesion: defective mtDNA- or nuclear-encoded complex-I component/maintenance protein.
Respiratory dysfunction: impaired NADH-to-ubiquinone electron transfer and reduced proton-gradient efficiency.
Metabolic stress: diminished ATP reserve, altered NADH/NAD+ redox balance, and increased electron leak/ROS.
Cellular response: altered mitochondrial dynamics, transport, mitophagy, membrane potential, calcium/redox signaling, and heightened apoptotic susceptibility.
Selective tissue injury: RGC somata and their long, partly unmyelinated, energy-intensive axons—especially the papillomacular bundle—fail.
Clinical manifestation: central/centrocecal field loss, dyschromatopsia, severe central acuity loss, RNFL/GCL thinning, and optic atrophy. (layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)

Complex I is embedded in the mitochondrial inner membrane and normally oxidizes NADH while reducing ubiquinone. Idebenone’s rationale is to accept electrons through NQO1 and deliver them downstream to complex III, partly bypassing complex I while also limiting oxidative injury. (zeppieri2025isolatedandsyndromic pages 13-14, lee2024hereditaryopticneuropathies pages 4-5, layrolle2024theopticnerve pages 2-4)

Suggested GO terms: oxidative phosphorylation (GO:0006119); apoptotic process (GO:0006915); mitochondrial electron transport, NADH to ubiquinone; ATP synthesis coupled electron transport; reactive-oxygen-species metabolic process; mitophagy; mitochondrial transport. GO cellular components: mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), respiratory-chain complex I. Cell Ontology: retinal ganglion cell; astrocyte and oligodendrocyte may be secondary participants. Exact current IDs should be release-validated.

Immune activation is not the primary mechanism, although secondary gliosis/inflammation may accompany degeneration. MRI abnormalities can resemble inflammatory demyelination, explaining frequent misdiagnosis.

7. Anatomical structures affected

The primary organ is the eye/afferent visual system. At tissue level, the retinal ganglion-cell layer, RNFL, optic disc, papillomacular bundle, and optic nerve are affected. MRI and pathology show downstream involvement of optic chiasm, optic tracts, lateral geniculate nuclei, optic radiations, and visual cortex. Histopathology has found up to approximately 95% reduction in temporal fibers and 40% reduction in optic-nerve cross-sectional area compared with controls. Disease is ultimately bilateral, often sequential and mildly asymmetric early. (layrolle2024theopticnerve pages 2-4)

Suggested UBERON: retina (UBERON:0000966), optic nerve, optic chiasm, optic tract, lateral geniculate nucleus, and visual cortex; validate exact release-specific IDs. Subcellular localization is the mitochondrial inner membrane/complex I.

8. Temporal development

A practical staging system is:

Asymptomatic carrier: normal acuity, although subtle color, electrophysiologic, OCT, or microvascular abnormalities may occur.
Subacute, <6 months: rapid visual decline, disc hyperemia/telangiectasia, RNFL swelling, early GCL loss.
Dynamic, 6–12 months: continued structural loss, transition from swelling to atrophy; some eyes begin recovery.
Chronic, >12 months: stable severe central deficit and optic atrophy, with possible delayed recovery.

The fellow eye is most vulnerable in the first weeks to months. This and the period before extensive GCL/RNFL loss constitute the strongest opportunity for intervention. Spontaneous or treatment-associated improvement may begin after approximately one year and continue for years; it is recovery rather than true remission because the causal genotype persists. (zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 2-4, iorga2025evaluationofvisual pages 1-2, catarino2017useofidebenone pages 5-6)

9. Inheritance and population

Classical LHON is maternally inherited: all children of a woman carrying the mtDNA variant may inherit it, while affected men do not transmit their mtDNA. Penetrance is incomplete, age-dependent, sex-biased, and family-specific. Expressivity is variable; anticipation is not established. Germline mosaicism is less relevant than heteroplasmy/mitotic segregation. Consanguinity is not important for classical mtLHON but may increase arLHON risk. Nuclear arLHON follows autosomal-recessive inheritance, giving a 25% affected-child risk when both parents carry pathogenic alleles in the same gene.

Manifest-disease prevalence in Europe is often reported between 1/27,000 and 1/50,000. A rigorous 2024 Madrid study identified 37 confirmed cases: observed prevalence 0.55/100,000 and capture–recapture prevalence 0.79/100,000, 43.6% higher than observed; sex-specific estimates were 1.15/100,000 in men and 0.43/100,000 in women, with a male:female ratio of 2.4:1. This study also showed that automated health-record ascertainment had low positive predictive value, emphasizing clinician confirmation. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2)

Founder effects occur: m.14484T>C is enriched in some French-Canadian pedigrees, while DNAJC30 p.Tyr51Cys is prominent in Eastern Europe. Carrier frequency is much higher than disease prevalence because penetrance is low.

10. Diagnostics

Clinical and functional evaluation

Urgent neuro-ophthalmic assessment should document best-corrected visual acuity, color vision, contrast sensitivity, automated visual fields, pupils, dilated fundus examination, fundus photography, and spectral-domain OCT of peripapillary RNFL and macular GCL/GCC. OCT can reveal GCL loss before obvious optic atrophy and helps distinguish LHON from inflammatory optic neuritis. Visual evoked potentials and pattern electroretinography/photopic negative response can document RGC dysfunction but are not required for molecular confirmation. MRI of brain and orbits with contrast is useful in atypical cases to exclude inflammation, compression, and demyelination; LHON can nevertheless show optic-nerve/chiasmal T2 abnormalities. (esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 2-4, NCT02652767 chunk 2)

Routine blood tests should be directed at mimics or modifiers: B12 with methylmalonic acid/homocysteine when indicated, folate, thiamine, copper, CBC, metabolic panel, and toxic-exposure testing. Lactate may be normal and is neither sensitive nor specific. Biopsy is generally unnecessary.

Genetic workflow

Test blood for m.11778G>A, m.3460G>A, and m.14484T>C.
If negative but suspicion remains, sequence the entire mitochondrial genome with heteroplasmy-sensitive methods and assess deletion/coverage quality.
If mtDNA testing is unrevealing, use an inherited-optic-neuropathy/nuclear mitochondrial panel including at least DNAJC30, NDUFS2, NDUFA12, MCAT, NDUFAF5, and differential genes such as OPA1.
WES/WGS is useful for unresolved or syndromic disease; WGS may better capture mtDNA and structural/noncoding variation, but laboratory validation is required.
Test the maternal lineage or siblings for segregation and counseling. (morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2)

CMA, karyotyping, FISH, and repeat-expansion tests are not first-line. RNA-seq, proteomics, metabolomics, epigenomics, and liquid biopsy are investigational, not standard diagnostics.

Differential diagnosis

Major alternatives are inflammatory optic neuritis associated with multiple sclerosis, AQP4-NMOSD or MOGAD; dominant optic atrophy; toxic/nutritional optic neuropathy; compressive optic neuropathy; ischemic optic neuropathy; glaucoma; macular disease; and other mitochondrial syndromes. LHON is favored by painless sequential central loss, male/maternal pedigree, disc telangiectasia without leakage, early macular GCL loss, poor spontaneous early recovery, and a pathogenic genotype. Prompt distinction matters because corticosteroids/plasma exchange treat inflammatory disease but not primary LHON. (morgia2024recognizingleber’shereditary pages 1-2)

No population newborn screening is established. Cascade testing of maternal relatives and targeted testing of at-risk siblings in arLHON are appropriate after counseling.

11. Outcome and prognosis

LHON usually does not directly shorten life expectancy, and disease-specific survival statistics are not meaningful for isolated disease. Morbidity is substantial because severe central blindness occurs during education and working life. LHON-plus disease may add neurologic or cardiac risk and warrants phenotype-directed surveillance.

Spontaneous recovery is genotype-dependent: approximately 37–71% or as high as 70% for m.14484T>C, 4–23% for m.11778G>A, and 15–25% for m.3460G>A in cited series. Recovery definitions and follow-up differ substantially. Favorable factors include m.14484T>C, younger/childhood onset, larger residual RNFL/GCL reserve, and possibly earlier treatment; m.11778G>A generally has the poorest natural prognosis. (morgia2024recognizingleber’shereditary pages 1-2, catarino2017useofidebenone pages 5-6)

12. Treatment

Idebenone

Idebenone is a short-chain benzoquinone/CoQ analog and antioxidant. The standard European regimen is 900 mg/day—300 mg three times daily with food. Consensus practice favors initiation as soon as possible, preferably within one year of onset, and continuation for at least one year; because recovery can be delayed, two years or continuation until a stable plateau is often considered. It is the only EMA-authorized disease-specific treatment in the gathered evidence. (lee2024hereditaryopticneuropathies pages 2-4, catarino2017useofidebenone pages 5-6, zeppieri2025isolatedandsyndromic pages 13-14)

RHODOS enrolled 85 patients and missed its prespecified primary endpoint, but secondary analyses favored idebenone. LEROS compared 199 treated patients with 372 external natural-history controls and found significantly more clinically relevant benefit at 12 months. Benefit varied by stage and genotype: subacute/dynamic benefit was clearest for m.11778G>A; chronic m.11778G>A and m.14484T>C groups showed consistent benefit, whereas m.3460G>A showed less effect. This is meaningful but not equivalent to a contemporaneous randomized comparison. (lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 4-5)

Common trial adverse events were generally mild—nasopharyngitis 25.5%, headache 23.6%, and cough 10.9% in the cited RHODOS analysis. Candidate NQO1 low-expression genotypes may predict poorer response, but routine NQO1-guided prescribing is not yet established. (catarino2017useofidebenone pages 5-6, lee2024hereditaryopticneuropathies pages 4-5)

NCIt suggestions: Idebenone; antioxidant; pharmacologic intervention. Verify current NCIt concept codes before ingestion.

Gene therapy

Lenadogene nolparvovec (GS010) uses intravitreal rAAV2/2 to deliver a nuclear-compatible wild-type ND4 with a mitochondrial targeting sequence—allotopic expression. RESCUE was a randomized, quadruple-masked phase III trial in 39 patients with ≤6 months’ visual loss; one eye received 9×10^10 vector genomes and the fellow eye sham. Both eyes improved, undermining the within-patient comparison, plausibly because vector/DNA or biological signaling crossed the optic pathways. (lee2024hereditaryopticneuropathies pages 4-5, NCT02652767 chunk 1)

REFLECT enrolled 98 patients with ≤1 year of loss and compared bilateral active injection with active first-eye/placebo fellow-eye treatment. RESTORE followed 62 RESCUE/REVERSE participants to five years and assessed BCVA, clinically relevant recovery, adverse events, and VFQ-25 quality of life. These studies support durable biological activity, but bilateral improvement after unilateral dosing, natural recovery, and absence of an independent untreated group limit causal effect estimates. (NCT03406104 chunk 1, NCT03293524 chunk 1)

Relevant records and URLs:

RESCUE, NCT02652767: https://clinicaltrials.gov/study/NCT02652767.
RESTORE, NCT03406104: https://clinicaltrials.gov/study/NCT03406104.
REFLECT, NCT03293524: https://clinicaltrials.gov/study/NCT03293524.
Historical natural history, NCT01892943, 306 records: https://clinicaltrials.gov/study/NCT01892943. (NCT01892943 chunk 1, NCT02652767 chunk 1, NCT03406104 chunk 1, NCT03293524 chunk 1)

As of the 2023–2024 literature, gene therapy remained investigational/not routine, and the European marketing application had been withdrawn. New trials should not be represented as approved care. NCIt suggestions: gene therapy (NCIt C15238), viral-vector therapy, intravitreal injection.

Other and supportive approaches

Brimonidine, cyclosporine, EPI-743/vatiquinone, elamipretide, bezafibrate, nicotinamide, mitochondrial biogenesis agents, stem cells, and mitochondrial gene editing/replacement remain experimental or unsupported for routine LHON care. The completed bezafibrate trial is NCT04561466; early rAAV2-ND4 studies include NCT01267422 and NCT03153293. No surgery restores the optic nerve. Low-vision rehabilitation, assistive technology, orientation/mobility training, occupational/educational accommodations, psychological care, and management of depression are essential. (zeppieri2025isolatedandsyndromic pages 13-14, lee2024hereditaryopticneuropathies pages 4-5)

13. Prevention

Primary prevention in carriers: do not smoke; avoid heavy alcohol and recreational/occupational mitochondrial toxins; maintain adequate nutrition; screen and treat B12 deficiency; review potentially optic-toxic drugs; and educate carriers about urgent assessment for new color or central-vision changes. No vaccine or proven prophylactic medicine applies.

Secondary prevention: cascade genetic testing, baseline neuro-ophthalmic assessment, rapid OCT/genetic confirmation after first-eye symptoms, and early idebenone where locally indicated. Routine population screening is not justified by current evidence.

Tertiary prevention: protect residual vision, avoid further mitochondrial insults, treat systemic LHON-plus disease, provide low-vision and psychological rehabilitation, and monitor the fellow eye during the high-risk interval.

Genetic counseling must explain maternal transmission, incomplete penetrance, inability to predict precisely who will convert, and different autosomal-recessive risks. Reproductive options include prenatal testing and preimplantation genetic testing; mitochondrial donation/replacement is jurisdiction-dependent and raises regulatory and ethical issues.

14. Other species and natural disease

No well-established, naturally occurring companion-animal or livestock disease is accepted as a direct LHON ortholog, and LHON has no zoonotic potential. Complex-I genes and RGC bioenergetics are deeply conserved, but veterinary optic neuropathies should not automatically be labeled LHON. Accordingly, no reliable VBO breed association or nonhuman natural-disease prevalence can be assigned from current evidence.

Nonhuman primates have been used to study AAV2 vector trafficking: vector transfer toward the contralateral optic pathway offers a mechanistic explanation for bilateral improvement after unilateral treatment. This is an induced experimental observation, not natural disease. (lee2024hereditaryopticneuropathies pages 4-5)

15. Model organisms and experimental systems

Cybrids and fibroblasts: Patient mtDNA can be placed in a standardized nuclear background to isolate mitochondrial effects. Cybrids reproduce complex-I/ROS phenotypes but are often non-neuronal and cannot model tissue architecture or sex/environmental penetrance.

Patient-derived iPSC-RGCs: These preserve patient nuclear and mitochondrial backgrounds. LHON-RGCs show abnormal morphology, reduced mitochondrial function/transport, altered signaling, and increased death. In a mitochondrial-replacement model, replacing mutant mtDNA generated isogenic corrected cells and rescued the increased RGC-death phenotype. These models support causality and are useful for drug screening, but differentiation variability and immature cellular state remain limitations.

Retinal organoids: Three-dimensional systems improve cell–cell context and can model RGC/axon loss, mitochondrial membrane-potential and ATP defects, and mitophagy. They still lack a mature vascularized optic nerve and long-range brain connections.

Rodent models: Induced complex-I-deficient and allotopic ND4-expression models reproduce selected RGC loss or treatment biology. No mouse fully captures human incomplete penetrance, maternal pedigree, papillomacular-bundle anatomy, and sequential bilateral onset. Ndufs4 models are broader complex-I disease models rather than exact classical LHON.

Applications: mechanism dissection, modifier validation, AAV biodistribution/safety, idebenone and antioxidant testing, CRISPR/mitochondrial-editing feasibility, and biomarker development. Robust translational conclusions require convergence across human cohorts, isogenic cells, organoids, and in-vivo systems.

Recent developments and expert assessment

Recognition of nuclear arLHON (2023): DNAJC30 and additional nuclear genes require a diagnostic pathway beyond the three primary mtDNA variants, particularly in Eastern European cases. This is a major shift from the historical “exclusively maternal” model. (zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 1-2)
Improved diagnostic guidance (2024): experts emphasize early OCT recognition and immediate targeted mtDNA testing to avoid misdiagnosis as optic neuritis, followed by full mtDNA sequencing and nuclear testing when necessary. (morgia2024recognizingleber’shereditary pages 1-2)
Population ascertainment (2024): the Madrid capture–recapture study showed that routine administrative sources undercount LHON and have poor positive predictive value without clinician validation. This argues for specialist-confirmed rare-disease registries.
Pharmacogenetic refinement (2024): NQO1 expression variants may explain some idebenone nonresponse, but prospective validation is required before genotype-guided therapy. (lee2024hereditaryopticneuropathies pages 4-5)
Gene-therapy interpretation: long-term improvement is encouraging, but contralateral-eye improvement after unilateral injection means that the fellow eye is not a true independent placebo. Authoritative reviews therefore regard allotopic therapy as promising but not yet definitive routine treatment. (lee2024hereditaryopticneuropathies pages 4-5, NCT02652767 chunk 1, NCT03406104 chunk 1)

Key source links and publication dates

Esmaeil A, Ali A, Behbehani R. Frontiers in Ophthalmology, January 2023. DOI: https://doi.org/10.3389/fopht.2022.1077395. The abstract summarizes LHON as respiratory-chain dysfunction that “eventually leads to apoptosis of retinal ganglion cells.” (esmaeil2023leber’shereditaryoptic pages 1-2)
Lenaers G et al. Brain, April 2023. DOI: https://doi.org/10.1093/brain/awad131. Abstract: “The discovery of arLHON cases breaks with the dogma of exclusive maternal inheritance.” (zeppieri2025isolatedandsyndromic pages 2-4)
Layrolle P et al. Biomedicines, March 2024. DOI: https://doi.org/10.3390/biomedicines12030584. Abstract: “Environmental factors are critical in LHON triggering or severity.” (layrolle2024theopticnerve pages 1-2)
Lee SK et al. Journal of Clinical & Translational Ophthalmology, June 2024. DOI: https://doi.org/10.3390/jcto2030006. (lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 4-5)
La Morgia C et al. Frontiers in Neurology, September 2024. DOI: https://doi.org/10.3389/fneur.2024.1466275. Abstract: “Given the availability of a specific treatment for LHON, its early diagnosis is imperative.” (morgia2024recognizingleber’shereditary pages 1-2)
Open Targets disease–target evidence, accessed through MONDO:0010788. (OpenTargets Search: Leber hereditary optic neuropathy)

Evidence gaps and curation cautions

Incidence is poorly quantified; prevalence varies with ascertainment and founder effects. Exact phenotype frequencies outside the core ocular syndrome are uncertain. No validated epigenetic or circulating biomarker predicts conversion. Environmental associations beyond smoking/heavy alcohol are mostly observational. Idebenone evidence combines randomized, follow-up, real-world, and externally controlled data with different recovery definitions. Gene-therapy efficacy remains difficult to isolate from natural recovery and bilateral vector effects. Ontology identifiers marked “verify” in the embedded table should be checked against current HPO, GO, CL, UBERON, CHEBI, NCIt, ICD-11, and Orphanet releases before database ingestion.

References

(zeppieri2025isolatedandsyndromic pages 2-4): Marco Zeppieri, Caterina Gagliano, Marco Di Maita, Alessandro Avitabile, Giuseppe Gagliano, Edoardo Dammino, Daniele Tognetto, Maria Francesca Cordeiro, and Fabiana D’Esposito. Isolated and syndromic genetic optic neuropathies: a review of genetic and phenotypic heterogeneity. International Journal of Molecular Sciences, 26:3892, Apr 2025. URL: https://doi.org/10.3390/ijms26083892, doi:10.3390/ijms26083892. This article has 5 citations.
(morgia2024recognizingleber’shereditary pages 1-2): Chiara La Morgia, Maria Lucia Cascavilla, Anna Maria De Negri, Marcello Romano, Fabrizio Canalini, Silvia Rossi, Diego Centonze, and Massimo Filippi. Recognizing leber’s hereditary optic neuropathy to avoid delayed diagnosis and misdiagnosis. Frontiers in Neurology, Sep 2024. URL: https://doi.org/10.3389/fneur.2024.1466275, doi:10.3389/fneur.2024.1466275. This article has 14 citations and is from a peer-reviewed journal.
(lee2024hereditaryopticneuropathies pages 1-2): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.
(layrolle2024theopticnerve pages 2-4): Pierre Layrolle, Christophe Orssaud, Maryse Leleu, Pierre Payoux, and Stéphane Chavanas. The optic nerve at stake: update on environmental factors modulating expression of leber’s hereditary optic neuropathy. Biomedicines, 12:584, Mar 2024. URL: https://doi.org/10.3390/biomedicines12030584, doi:10.3390/biomedicines12030584. This article has 10 citations.
(esmaeil2023leber’shereditaryoptic pages 1-2): Ali Esmaeil, Ali Ali, and Raed Behbehani. Leber’s hereditary optic neuropathy: update on current diagnosis and treatment. Frontiers in Ophthalmology, Jan 2023. URL: https://doi.org/10.3389/fopht.2022.1077395, doi:10.3389/fopht.2022.1077395. This article has 34 citations.
(layrolle2024theopticnerve pages 1-2): Pierre Layrolle, Christophe Orssaud, Maryse Leleu, Pierre Payoux, and Stéphane Chavanas. The optic nerve at stake: update on environmental factors modulating expression of leber’s hereditary optic neuropathy. Biomedicines, 12:584, Mar 2024. URL: https://doi.org/10.3390/biomedicines12030584, doi:10.3390/biomedicines12030584. This article has 10 citations.
(lee2024hereditaryopticneuropathies pages 2-4): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.
(lee2024hereditaryopticneuropathies pages 4-5): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.
(NCT02652767 chunk 1): Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation. GenSight Biologics. 2016. ClinicalTrials.gov Identifier: NCT02652767
(NCT03406104 chunk 1): RESCUE and REVERSE Long-term Follow-up. GenSight Biologics. 2018. ClinicalTrials.gov Identifier: NCT03406104
(NCT03293524 chunk 1): Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year. GenSight Biologics. 2018. ClinicalTrials.gov Identifier: NCT03293524
(OpenTargets Search: Leber hereditary optic neuropathy): Open Targets Query (Leber hereditary optic neuropathy, 24 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(NCT01892943 chunk 1): Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey. Santhera Pharmaceuticals. 2013. ClinicalTrials.gov Identifier: NCT01892943
(iorga2025evaluationofvisual pages 1-2): Raluca Eugenia Iorga, Andreea Dana Moraru, Răzvana Sorina Munteanu-Dănulescu, Delia Urdea, and Ciprian Danielescu. Evaluation of visual and optical coherence tomography outcomes in patients with leber’s hereditary optic neuropathy treated with idebenone. Life, 15:1172, Jul 2025. URL: https://doi.org/10.3390/life15081172, doi:10.3390/life15081172. This article has 1 citations.
(NCT02652767 chunk 2): Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation. GenSight Biologics. 2016. ClinicalTrials.gov Identifier: NCT02652767
(catarino2017useofidebenone pages 5-6): Claudia B. Catarino and Thomas Klopstock. Use of idebenone for the treatment of leber’s hereditary optic neuropathy: review of the evidence. ArXiv, 5:232640981773111, Sep 2017. URL: https://doi.org/10.1177/2326409817731112, doi:10.1177/2326409817731112. This article has 10 citations.
(zeppieri2025isolatedandsyndromic pages 13-14): Marco Zeppieri, Caterina Gagliano, Marco Di Maita, Alessandro Avitabile, Giuseppe Gagliano, Edoardo Dammino, Daniele Tognetto, Maria Francesca Cordeiro, and Fabiana D’Esposito. Isolated and syndromic genetic optic neuropathies: a review of genetic and phenotypic heterogeneity. International Journal of Molecular Sciences, 26:3892, Apr 2025. URL: https://doi.org/10.3390/ijms26083892, doi:10.3390/ijms26083892. This article has 5 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Leber Hereditary Optic Neuropathy: Comprehensive Disease-Characteristics Report

Executive summary

1. Disease information

Definition and identifiers

2. Etiology, risk, and protective factors

Causal factors

Genetic susceptibility and modifiers

Environmental and lifestyle risks

Protective factors and gene–environment interaction

3. Phenotypes

Core ocular phenotype

Frequency, onset, severity, and progression

LHON-plus

Quality of life

4. Genetic and molecular information

Variant classes and population frequency

Epigenetics and omics

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical and functional evaluation

Genetic workflow

Differential diagnosis

11. Outcome and prognosis

12. Treatment

Idebenone

Gene therapy

Other and supportive approaches

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Recent developments and expert assessment

Key source links and publication dates

Evidence gaps and curation cautions

Artifacts